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You know when you know, 
and when you do not know, you do not know, 
such is true knowledge. 
 
Confucius 
Ancient Chinese educator 
 
 
 
Never doubt that a small group of thoughtful,  
committed citizens can change the world. 
 Indeed, it is the only thing that ever has. 
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Abstract 
 
 
       Despite the importance of proteasome-mediated proteolysis in synaptic plasticity, 
protein quality control, and cell regulation, little is known about proteasome composition 
and regulation in the brain. This thesis represents the first detailed study of mammalian 
brain proteasomes. Using a new affinity purification method, 26S proteasomes were 
isolated from the cytosolic and the synaptic compartments of the rat cortex. The proteins 
associated with the 26S proteasome were purified and analyzed by tandem mass 
spectrometry. A total of 30 proteasome-interacting proteins were identified in the brain. 
Several differences were seen in the spectrum of proteasome-associated proteins in the 
cytosol and the synaptosome. For example, the proteasome-associated protein ECM29 
was found only in the cytosolic 26S proteasome, and the ubiquitin-binding factor 
TAX1BP1 only in the synaptic 26S proteasome. These findings allowed for further 
investigations into the interplay between proteasome regulation and synaptic plasticity. 
      Neuronal exposure to the neurotransmitter NMDA caused the degradation of 19S 
particles, resulting in lower levels of 26S proteasomes. The levels of ubiquitin conjugates 
also decreased, as did two proteasome-bound ubiquitin ligases, UBE3A/E6-AP and 
HUWE1/ARF-BP1, both of which have been linked to neurogenetic disorders associated 
with mental retardation. Thus, in the brain, proteasomes have a characteristic set of 
associated proteins that may serve as regulators or cofactors. Moreover, the content and 
pattern of associated proteins can vary with synaptic activity, in a manner likely to 
influence synaptic plasticity.  
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Chapter 1 
 
 Introduction 
 
 
 
 
 
 
 
 
 
 
 
       Neurons have highly polarized morphologies and the connection properties between 
neurons are constantly modified through mechanisms called synaptic plasticity. In the 
central nervous system of higher animals, each neuron is postmitotic and basically 
irreplaceable during the life span of the animal. As we investigate these unique properties 
of neurons, it is becoming clear that the proteome of a neuron is also very interesting to 
study. At the level of individual synapses, the local proteome is dynamic and modifiable. 
Protein synthesis and degradation work hand-in-hand to remodel synaptic properties to 
allow for synaptic plasticity. At the whole-cell level, the neuron faces the challenge that it 
cannot get rid of aberrant proteins through cell division, but has to deal with them 
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internally. The degradation of aberrant and toxic proteins is crucial to the long-term 
viability of the neuron.  
      The major site of protein degradation in the eukaryotic cell is the proteasome 
complex. This thesis represents the first detailed study on neuronal proteasomes, and 
reveals that they contain many additional previously unknown components. By observing 
compositional differences in neuronal proteasomes compared to other mammalian cells, 
it appears that the proteasome complex has evolved differently in neurons to meet their 
specialized proteolytic demands. Moreover, neuronal proteasomes also show dynamic 
changes associated with changes in neuronal activity. Characterizing the basic machinery 
of protein degradation is an important first step toward understanding the crucial role of 
proteolysis in neuronal function and dysfunction.  
 
1.1. Protein degradation is a fundamental cellular process 
     It the history of biological sciences, our understanding of catabolic processes often 
lags behind that of corresponding anabolic processes. Before we understood the basic 
chemical properties of living organisms, scientists assigned the vital forces that perform 
chemical transformations to mysterious agents called enzymes. Later it was discovered 
that enzymes are made of proteins, or polypeptides. The quest to understand the synthesis 
of proteins and their link to the genetic material eventually led to the discovery of the 
“central dogma” of molecular biology [1]. Around that time, little attention was paid to 
the ultimate fate of proteins. It was often assumed that proteins are stable entities that do 
not turn over, because polypeptides do not undergo spontaneous hydrolysis at 
physiological conditions.  
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      The first indication that proteins are not stable entities but undergo constant turnover 
came from isotope labeling studies in the late 1930s [2]. In the 1950s, protein degradation 
was shown to be adenosine triphosphate (ATP)-dependent [3]. The result appeared 
surprising because the hydrolysis of the peptide bond is thermodynamically favorable. 
However, these studies received little attention at the time because the function and 
mechanism of protein degradation were poorly understood. It was not until the 1980s that 
we finally uncovered the major proteolytic sites of the eukaryotic cell: the proteasome 
and the lysosome. The proteasome is a large protein complex and its proteolytic activity 
is confined to its interior. The lysosome is a membrane-bound organelle with enzymes to 
breakdown proteins and other macromolecules. The confinement of proteolytic activities 
within these structures help prevent non-specific proteolysis [4]. The energy expenditure 
of degradation is related to the selection and delivery of substrates to the proteolytic 
machinery [5]. In many cases, proteins destined for degradation are tagged by ubiquitin, a 
76 amino acid protein [6, 7]. 
       Today, it is well-accepted that the precise regulation of proteolysis underlies many 
fundamental cellular processes, such as cell division, protein quality control, transcription, 
DNA repair, and so on [4, 6, 8]. The average protein in yeast has a half-life of <2 hours 
[9], and as much as one third of the pool of newly synthesized proteins is instantly 
degraded for quality control purposes, mostly carried out by the proteasome [10]. There 
are several fundamental reasons to degrade proteins inside the cell: when they are no 
longer required or need to be actively removed, when they are abnormal (misfolded or 
chemically damaged), and when a balance between degradation and synthesis is required 
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to maintain desired protein levels. It is therefore not surprising that protein degradation 
regulates most aspects of cell biology.   
 
1.2. Neurons have unique protein degradation demands 
      If all cells require regulated protein degradation to function properly, why are nerve 
cells of particular interest? The unique morphology of neurons—with specialized zones 
for presynaptic neurotransmitter release and postsynaptic receptor activation, and the 
plasticity of synapses—tightly coupled to changes in the synaptic proteome, impose 
special challenges on the cellular machinery for both protein synthesis and degradation 
[11, 12].  Within this context, we aim to understand how degradative pathways are 
tailored to support the physiology of neurons and facilitate key brain functions such as 
learning and memory [13, 14]. Due to its morphology, the neuron has very high surface-
area-to-volume ratios. Thus, membrane protein turnover is an important issue for the 
neuron. Because the space within the neuron is highly compartmentalized, there is also a 
need for compartment-specific regulation of protein degradation to modulate synaptic 
function during learning, memory, and development [14-17].  
      Since neurons are postmitotic cells, they cannot get rid of aberrant proteins through 
asymmetric cell division [18]. Throughout the lifespan of a higher animal, each neuron 
must vigilantly protect itself against protein misfolding and oxidation. Most 
neurodegenerative disorders in humans are characterized by the presence of pathological 
protein aggregates, indicative of a failure in protein quality control. It is therefore 
important to understand protein quality control mechanisms in normal neurons and how 
they are affected during neurodegenerative conditions.  
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     In sum, due to their unique morphologies, requirements for synaptic plasticity, internal 
compartmentalization, and the postmitotic life cycle, neurons have very unique protein 
degradation demands. It is of great interest to understand how neurons have evolved to 
meet these specialized demands. In particular, this thesis will investigate the unique 
properties of neuronal proteasome composition and regulation. 
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Chapter 2 
 
 Review of the literature 
 
 
 
 
 
 
 
 
 
 
 
 
         
        Compared to protein synthesis, the molecular mechanism of protein degradation is 
much less understood. While there are two major proteolytic sites in the cell, the 
proteasome and the lysosome, specific details about each protein’s termination are in 
most cases unclear. It is often difficult to determine what triggers the degradation of a 
particular protein, and how it is delivered and handled by the proteolytic machinery. This 
chapter will briefly describe the basic principles of the proteasomal and lysosomal 
proteolytic pathways. An overview will be given on the emerging evidence on the 
importance proteasome-mediated degradation in synaptic plasticity, and the link between 
protein degradation and neurodegeneration. Moreover, it will discuss how proteasome 
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function is dynamically regulated in the cell, especially through a network of proteasome-
interacting proteins.  
 
2.1    Degradation by the UPP and the lysosome 
       Most cellular proteins are degraded by the proteasome and/or the lysosome. We can 
further classify proteolytic processes into several major pathways (Table 2-1). The most 
important and versatile of all proteolytic pathways is the ubiquitin-proteasome pathway 
(UPP), which degrades the majority of intracellular and endoplasmic reticulum (ER) 
proteins. It is also the focus of this study.  
 
 
 
 
Table 2-1. Major proteolytic pathways in the eukaryotic cell 
        
Proteolytic pathway Substrates Substrate ubiquitination 
26S proteasome intracellular proteins, ER proteins, outer mitochondrial membrane proteins mostly 
20S proteasome partially unfolded proteins? oxidized proteins? no 
endosome-lysosome  plasma membrane proteins, endocytosed proteins sometimes 
autophagy intracellular proteins, proteins in bulk  sometimes? 
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The UPP 
         Ubiquitin is a small protein of 76 amino acids. Ubiquitination (or ubiquitylation) is 
a posttranslational modification that forms an isopeptide bond between a lysine residue 
on the protein and the carboxyl terminus of ubiquitin. The system to ubiquitinate a 
protein consists of four different classes of enzymes: E1–E4. First, ubiquitin is covalently 
conjugated to the E1 (ubiquitin activating enzyme) in an ATP-dependent reaction, 
followed by transfer to the E2 (ubiquitin conjugating enzyme). The E3 (ubiquitin-protein 
ligase) transfers the ubiquitin from the E2 to the substrate protein [8]. After the first 
ubiquitin is attached (monoubiquitination), the E3 can elongate the ubiquitin chain by 
creating ubiquitin-ubiquitin isopeptide bonds. The E4 (chain elongation factor) is a class 
of E3-like enzymes that only catalyzes chain extension [19]. Ubiquitin has seven lysines 
(K6, K11, K27, K29, K33, K48, and K63), all of which are available and indeed used in 
vivo for chain extension [20]. The process of ubiquitination is schematically presented in 
Figure 2-1. The significance of complex ubiquitination patterns is only partially 
understood: K48 and K11 chains are the most common signals for degradation by the 26S 
proteasome, while monoubiquitination and K63 chains do not generally specify 
degradation but have other biological functions including endocytosis [19, 21].  
      The E3 is largely responsible for target recognition in this system via physical 
interactions with the substrate. The large number of E3 genes in eukaryotic genomes [22] 
(see Table 2-2) reflects the highly specific nature of substrate recognition in UPP-
mediated degradation [23]. Several classes of UPP factors are involved in the 
presentation of substrates to the proteasome: ubiquitinating enzymes (E1–E4), 
deubiquitinating enzymes (DUB), shuttling factors and chaperones. The organization of 
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these factors may differ for each substrate.  Figure 2-1 shows an example of how a 
protein’s ubiquitination pattern can be dynamically edited by E3s, E4s, and DUBs. When 
K48-polyubiquitinated, the protein can reach the proteasome by diffusion or with the 
assistance of chaperones and shuttling factors [24]. In some cases, the proteasome can 
also move toward the substrate [25]. After substrate-proteasome association, DUB and 
ATP-dependent unfoldase activities help the substrate to enter the proteolytic lumen of 
the proteasome[26]. The structure and heterogeneity of proteasomes are illustrated in Fig. 
2-2.  
 
 
 
 
Table 2-2.  Ubiquitination-related proteins encoded in four eukaryotic genomes 
 
Class Homo sapiens Mus musculus D. melanogaster S. cerevisiae 
E1 16 16 11 8 
E2 53 61 32 15 
E3 527 442 189 68 
DUB 74 78 27 20 
 
(compiled from ref. [22]) 
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Figure 2-1. A schematic representation of the UPP. Ubiquitination is carried out by a 
cascade of enzymes (E1, E2, E3). The ubiquitin chain can be further elongated and 
edited by E3/E4 enzymes and DUBs. K48 chains target substrates to 26S proteasomes 
for degradation. Substrates are deubiquitinated and unfolded at the proteasome before 
entering the proteolytic lumen of the 20S particle (see Fig. 2-2 for proteasome 
structure). ATP is consumed by E1 to activate ubiquitin and by the 19S Rpt subunits to 
unfold the substrate. K63 chains generally do not lead to proteasomal degradation. 
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Figure 2-2. Structure of the proteasome. The proteasome is a large, multi-subunit 
protease complex [26]. The 20S core complex is composed of four heptameric rings of 
α1-7 and β1-7 subunits. The proteolytic activities are conferred by three of the β 
subunits in the interior of the barrel. The 19S regulatory complex, or PA700, contains a 
hexameric ring of six AAA-ATPase subunits (Rpt1–6), and about a dozen non-ATPase 
(Rpn) subunits. The 19S receives the polyubiquitinated substrate, removes the ubiquitin 
and, using ATPase activity, unfolds it for translocation into the 20S chamber [26]. Due 
to experimental difficulties in characterizing proteasome heterogeneity, the 
nomenclature of proteasome subtypes is not yet standardized in the literature. Different 
proteasome subtypes and their nomenclature used in this thesis are presented in the 
figure. Here 26S proteasome will denote both singly- and doubly-capped species, since 
they both degrade polyubiquitinated proteins. In addition, many interacting proteins 
can associate stably or transiently with the proteasome. For instance, another regulatory 
complex of the 20S, called 11S/REG/PA28, is a heptameric ring of PA28 subunits (α, 
β, γ) and highly abundant in mammalian cells. This complex is thought to activate the 
20S by widening the pore [27]. The mix-and-match of 20S, 19S and 11S gives rise 
additional types of proteasomes [28].  
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Lysosome and autophagy 
        Lysosomes are organelles containing acid hydrolases to break down biopolymers 
and other biomolecules [29] (see Fig. 2-3). To breakdown plasma membrane proteins and 
endocytosed proteins, substrates are first endocytosed and eventually enter the proteolytic 
organelles including late endosomes and lysosomes. Many types of signals can regulate 
endocytosis and sorting, including monoubiquitination and K63-polyubquitination [7, 30]. 
Endocytosed proteins first arrive at early endosomes, and subsequently get sorted into 
recycling endosomes (for return to the surface by exocytosis) or multivesicular bodies [31] 
(for transport to late endosomes or lysosomes). The acid hydrolases in the lumen of 
lysosomes (pH 4-5) and late endosomes (pH 5-6) are highly active in acidic environments, 
but lose their activities in the cytosol (pH ~7.2). The confinement and the pH-dependence 
of hydrolases provide dual safeguards against accidental damage [29, 32]. Intracellular 
proteins can also enter lysosomes by several autophagy mechanisms [33]. In 
macroautophagy, large amounts of cytosolic materials or even organelles are surrounded 
by a double-membrane structure (autophagosome) which fuses with lysosomes. In 
microautophagy, a small amount of the cytoplasm is internalized through lysosomal 
invagination. In chaperone-mediated autophagy, proteins unfolded by the chaperone 
translocate into the lysosome through interactions with lysosome-associated membrane 
protein 2 (LAMP-2) [34]. During cellular starvation, cellular proteins can be non-
specifically degraded through macroautophagy. But little is known about how specific 
proteins are marked for autophagy [35]. Recent studies implicate that p62/sequestosome 
1 may facilitate the macroautophagy of ubiquitinated proteins [36].  
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Figure 2-3. Lysosome and autophagy. Lysosomes are organelles containing acid 
hydrolases to break down biopolymers and other biomolecules, including proteins. 
Lysosomes can also fuse with other organelles such as late endosomes and 
autophagosomes to degrade their internal contents. Endocytosed membrane proteins 
may be recycled back to the surface or degraded in late endosomes or lysosomes. Many 
types of signals can regulate endocytosis and sorting, including monoubiquitination 
(shown here) and K63-polyubquitination. Intracellular proteins can enter lysosomes by 
macroautophagy, microautophagy, or chaperone-mediated autophagy. 
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2.2   Synaptic plasticity requires protein degradation 
     As early as 1949, Hebb postulated that “some growth process or metabolic change” 
may underlie activity-dependent modifications of neuronal connectivity [37]. Since 
proteins are the molecular machines that mediate signal transduction, it is no surprise that 
protein synthesis and degradation are important for plasticity and memory [11]. Memory 
impairment caused by protein synthesis inhibitors was first demonstrated in the 1960s, 
and subsequently confirmed by many studies [38]. The repression of translation by 
anisomycin, cycloheximide, or puromycin do not affect learning but the retention of 
memory when the animal is tested hours or days later. Parallel findings using inhibitors 
of protein degradation were recently reported. Retrograde amnesia in rats was observed 
in one-trial inhibitory avoidance learning, when proteasome inhibitor lactacystin was 
injected into the CA1 region of the hippocampus at 1, 4, or 7 hours post-training, but not 
10 hours [39]. In another study, impaired fear learning by injection of anisomycin into the 
mouse hippocampus was rescued by lactacystin co-injection [40]. These findings 
implicate that protein synthesis and degradation work in an orchestrated manner to 
regulate synaptic functions that underlie learning and memory [11].  
      Since proteasome inhibitors can affect memory in animal behavior studies, what are 
the underlying molecular and cellular mechanisms? One of the first links between the 
UPP and synaptic plasticity came from the study of long-term facilitation (LTF) in 
Aplysia, which is similar to long-term potentiation (LTP) in higher animals, at the 
sensory-to-motor neuron synapse [41]. LTF and LTD are long lasting synaptic changes 
with enhanced neurotransmission, and in mammals the opposite effect is termed long-
term depression (LTD). During LTF induction, proteasome activity is required in the 
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soma of the presynaptic cell to degrade the regulatory subunit of cAMP-dependent 
protein kinase (PKA) [41-43]. It was also shown that synaptic strength can be locally 
regulated by the synaptic UPP. At the sensory-to-motor synapse, proteasome inhibition 
can lead to both presynaptic and postsynaptic changes including increases in the number 
of synaptic contacts, the length of sensory neuron processes, and the amplitude of 
glutamate-evoked postsynaptic potential [44]. Thus, the UPP can regulate synaptic 
plasticity by different mechanisms at different subcellular compartments.       
       Recent studies in mammals suggest that an intricate balance between protein 
synthesis and degradation underlies long-term plasticity and memory. For example, LTP 
in rat hippocampal slices can be disrupted by proteasome inhibitor lactacystin [45, 46]. 
However, this effect is rescued by translational inhibitor anisomycin [45]. Interestingly, 
anisomycin by itself also disrupts hippocampal LTP [47]. However, how synthesis and 
degradation are coordinated with respect to synaptic modulation remains currently 
unknown.  
 
UPP regulates synaptic modifications 
    Like in Aplysia, the UPP regulates synaptic transmission at both pre- and postsynaptic 
terminals in mammals.  At the presynapse of cultured hippocampal neurons, for example, 
the size of the recycling vesicle pool increases by 76% after 2 hours of proteasomal 
blockade, an effect that is independent of protein synthesis [48].  In hippocampal slices, 
proteasome inhibition leads to an increase in the frequency of miniature excitatory 
postsynaptic currents [49], which is largely abolished in transgenic animals lacking 
SCRAPPER, an E3 enzyme localized to the presynaptic membrane.  A key substrate of 
16 
 
 
 
SCRAPPER is RIM1, a Ca2+-dependent vesicle-priming factor. Together, SCRAPPER 
and RIM1 regulate how vesicle release responds to presynaptic calcium levels [49].  
Therefore, at the presynapse the UPP influences the size of the vesicle pool and vesicle 
release. 
        The UPP also regulates the abundance of proteins involved in the postsynaptic 
response, including ionotropic glutamate receptors and proteins comprising the 
postsynaptic density (PSD) [14, 50]. The PSD is an electron-dense structure adjacent to 
the postsynaptic membrane, visible in electron micrographs, that contains receptor 
channels, structural proteins and signal transduction proteins. It was shown that chronic 
blockade of action potential by tetrodotoxin led to the increase of certain PSD proteins 
(Shank, NR2B, PP1) and the decrease of some others (PSD-95, NR2A, CaMKIIα) [51]. 
The blockade of inhibitory neurotransmission by bicuculline induced opposite effects. 
However, changes in PSD composition were blocked when a proteasome inhibitor was 
co-applied, demonstrating the importance of proteolysis in restructuring the synapse in 
response to changes in neural activity. Figure 2-4 illustrates some of the proteolytic 
processes known to occur at the synapse.  
     The level of neurotransmitter receptors at the synapse is a major determinant of 
synaptic efficacy. In worms the ubiquitination of glutamate receptors reduces their levels 
at the synapse, possibly through endocytic mechanisms [52]. In mammals, the 
ubiquitination of AMPARs and NMDARs have also been observed [53, 54]. Moreover, 
the turnover of AMPARs at the synapse involves both proteasomal and lysosomal 
activities. AMPA-induced, clathrin-dependent endocytosis of AMPARs can be blocked 
by proteasome inhibition and by expression of dominant negative K48R ubiquitin [55]. 
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The depolarization of neurons causes proteasomes to rapidly redistribute into dendritic 
spines [25]. It has been suggested that UPP activity downregulates PSD95, and thereby 
disrupts the anchoring of AMPARs [56, 57]. Endocytic zones are localized laterally to 
the PSD in the dendritic spine [58], and hence the release of AMPARs from the PSD 
scaffold may indeed be a prerequisite for endocytosis (Fig. 2-4). After endocytosis, 
AMPARs reside in early endosomes, and may be sorted into recycling endosomes for 
surface reinsertion or into late endosomes/lysosomes for degradation, depending on 
subunit composition and whether NMDARs were simultaneously activated [59, 60]. The 
complex dynamics [61] of AMPARs’ degradation, synthesis, posttranslational 
modification, and trafficking is without doubt a key mechanism of synaptic plasticity that 
remains to be fully understood.  
     In spite of these recent progresses, most of the proteins degraded during synaptic 
remodeling remain unknown. The molecular mechanisms behind these proteolytic events 
are also difficult to elucidate. We still do not understand which UPP components are 
important at the synapses and how they work together, which is one of the focuses of this 
thesis study.  
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Figure 2-4. Degradation of synaptic proteins. The UPP regulates the recycling and the 
release of synaptic vesicles at the presynaptic terminal (axonal bouton, top). Released 
glutamate activates AMPA and NMDA receptors at the postsynaptic terminal (dendritic 
spine, bottom). This may trigger the polyubiquitination of PSD scaffolding proteins and 
the translocation of 26S proteasomes into spines. The degradation of PSD scaffolding 
proteins leads to the de-anchoring of AMPARs, which are endocytosed at the lateral 
zone of the spine. Endocytosed AMPARs marked for degradation are sorted into late 
endosomes/lysosomes containing acid hydrolases. In mature hippocampal neurons, 
endocytosis occurs along the entire dendrite and at the presynaptic terminal but not the 
shaft of axons [62]. In both cases, many internalized proteins are transported in 
multivesicular bodies to the soma for breakdown. Retrograde vesicular traffic requires 
dynein motors that travel toward the minus end of the microtubule. LE/Lys: late 
endosome/lysosome. MVB: multivesicular body   
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2.3   Neurodegeneration involves proteolytic dysfunction 
      A wide array of neurodegenerative disorders are known to occur in humans, and the 
majority of them are characterized by protein aggregates in the degenerating areas. While 
different proteins are found in the aggregates of different neurodegenerative disorders 
(Table 2-3), these proteins share a common feature: they are misfolded into the amyloid 
fibril structure [63]. The amyloid fibril structure is generally resistant to proteolysis and 
grows in size by converting normal proteins into their misfolded states. As a result of 
decreased degradation (not increased synthesis) and the growth of the fibrils, large 
protein inclusions are formed around or inside degenerating neurons [64]. Collectively, 
these disorders are now considered protein misfolding diseases, or “proteinopathies” of 
the central nervous system (CNS), which include Parkinson’s disease (PD), Alzheimer’s 
disease (AD), polyglutamine (polyQ) expansion diseases, and prion-related disorders [65] 
(see Table 2-3). In most cases, protein inclusions stain positively with antibodies against 
ubiquitin [65-67]. Curiously, abnormalities of just four proteins—α-synuclein, amyloid β, 
tau and TAR DNA binding protein (TDP-43)—appear to be associated with 80–90% of 
neurodegenerative dementias [68, 69].  
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Table 2-3. Neurodegenerative protein misfolding diseases 
 
Aggregate 
protein 
Aggregate 
location Related disorders 
Tau Intracellular tangles 
Alzheimer’s disease (AD), frontotemporal lobar 
dementia, corticobasal degeneration, Pick’s 
disease, progressive supranuclear palsy 
α-Synuclein Intracellular Lewy bodies 
Parkinson’s disease (PD), dementia with Lewy 
bodies (DLB), multiple system atrophy 
TDP-43 Intracellular frontotemporal lobar degeneration, amyotrophic lateral sclerosis 
PolyQ expansion 
proteins Intracellular 
Huntington’s disease, spinocerebellar ataxias, 
spinal and bulbar muscular atrophy, 
dentatorubral-pallidoluysian atrophy 
Amyloid β Extracellular plaques Alzheimer’s disease 
Bri2 Extracellular familial British/Danish dementias 
 
 
       
 
       The frequent detection of proteasomes and lysosomes around ubiquitin-positive 
aggregates in postmortem brains implies that proteins within these aggregates were 
marked for degradation but were not efficiently removed [65, 70]. Consistent with this 
model, characterization of Lewy bodies from dementia with Lewy bodies (DLB) and PD 
patients revealed that the major ubiquitinated protein was α-synuclein [71]. The ubiquitin 
chain length was between one and three, and K48 linkage was detected. It is known that 
K48 chains of four ubiquitins or longer is required for efficient targeting to the 
proteasome [72]. As such, the di- and tri-ubiquitinated α-synuclein species that have been 
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detected appear to be trapped intermediates that have failed to reach their proteolytic 
destination. It also implies that some of the misfolded α-synuclein has been successfully 
degraded by the proteasome, but the rate of proteolysis may not have been fast enough to 
overcome protein deposition in degenerating neurons.   
     Furthermore, overall proteasome activity in brain tissue decreases with aging, and 
further loss is observed in degenerative conditions such as AD and PD [73]. Hence, it has 
been proposed that neurodegeneration may be linked to degradative dysfunction by 
several mechanisms [65, 74]. In one possible scenario, the impairment of degradation 
may be responsible for the decline of neuronal health, while aggregate formation may be 
a secondary phenomenon. Alternatively, some other factors may impair neuronal health 
and cause protein aggregation, and in turn these aggregates interfere with normal 
proteolysis [75, 76] and cause further problems. To this date, it has been difficult to 
determine if protein aggregation is sufficient to cause neurodegeneration [77], and further 
studies of proteolytic pathways in the brain may provide insights into why aggregates 
form and how they impact cellular function.   
 
The UPP and PD  
     Dysfunction of the UPP [74, 78, 79] and lysosome-autophagy [80, 81] have been 
implicated in many neurological disorders. For instance, in the UPP, an increasing 
number of E3 genes are now linked to neurogenetic disorders, including UBE3A (E6-AP) 
in Angelman Syndrome, including UBR1 in Johanson-Blizzard syndrome [82], NHLRC1 
in Lafora’s disease [83], as well as Cul4B [84] and HUWE1 [85] in X-linked mental 
retardation. There is also a group of ~50 degenerative disorders mapped to mutations in 
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the lysosomal pathway, collectively called lysosomal storage diseases (LSD) because of 
intralysosomal accumulation of unmetabolized substances [86]. LSDs may affect 
multiple organs, but most affect the nervous system by compromising neuronal function.  
     Interesting links between the UPP and neurodegeneration have been found in 
mutations leading to familial PD. While most PD cases are idiopathic, the identification 
of monogenic mutations linked to hereditary forms of PD (about eight genes to date) 
provides new insights into the pathogenesis [87, 88]. One of the more common types of 
familial PD is caused by mutations in PARK2 [89], encoding the E3 ligase parkin. 
Mutations in PARK2 cause early disease onset with the loss of dopaminergic neurons in 
the substantia nigra, suggesting that UPP dysfunction may contribute to pathogenesis [79], 
while Lewy bodies are generally absent [89]. Moreover, recent studies indicate that two 
additional familial PD genes, PINK-1 (PARK6) and DJ-1 (PARK7), encode proteins that 
form an E3 complex with parkin [90]. The genetic association of UCHL1, a DUB, with 
familial and sporadic PD is somewhat controversial, but it is found in Lewy bodies [88, 
91]. It is also mutated in a form of neurodegenerative ataxia in mice that arises from 
spontaneous mutations, called gracile axonal dystrophy [92, 93]. These mice exhibit 
retrograde accumulation of amyloid β aggregates, but not α-synuclein, in gracile tract 
axons that control the hind limbs. This finding implies that deposits of aggregation-prone 
proteins may be a secondary effect of global UPP impairment, because UCH-L1 helps 
maintain the monomeric pool of ubiquitin [94]. As such, about half of the reported PD-
causing genes have already been linked to the UPP.  
      Recent transgenic mouse studies further support the hypothesis that UPP dysfunction 
can lead to PD and DLB. By inactivating the gene of a 19S proteasome subunit in 
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specific regions of the brain, the manipulated neurons show decreased 26S levels. 26S 
proteasome depletion in the cortex and midbrain dopaminergic neurons cause neuronal 
death and Lewy body (α-synuclein) deposition [95]. In humans, DLB and PD are also 
characterized by Lewy body accumulation in the cortical and midbrain dopaminergic 
neurons, respectively, and many patients eventually develop both. This also represents 
the first established murine model of DLB. Furthermore, in neuroblastoma cell lines, the 
overexpression of a mutant proteasome subunit also causes α-synuclein aggregation [96]. 
Therefore, UPP dysfunction is likely to contribute to both sporadic and hereditary forms 
of PD [97].   
 
2.4   Proteasome function is a regulated by multiple mechanisms 
    Since each protein is a unique three-dimensional object with a distinct folded structure 
and chemical properties, it is remarkable that the proteasome can adequately handle 
thousands of such objects. Although the recognition of proteolytic substrates is largely 
attributed to polyubiquitination, the proteasome still has to physically interact with each 
substrate and unfold it for degradation. We do not fully understand how this can be 
achieved, or why the UPP fails to remove aggregate-prone proteins like TDP-43 or tau in 
degenerating neurons. 
     Recent studies have shown that many properties of the proteasome can be regulated by 
the cell, including its cellular levels, localization, the complement of its interacting 
proteins, and posttranslational modification states [98, 99]. In the neuron, it has been 
shown that proteasome levels can decrease with aging [100]. Proteasomes also rapidly 
redistribute into dendritic spines in an activity-dependent manner [25]. Compared to other 
24 
 
 
 
cell types, neurons express much lower levels of proteasome activator PA28β [101], 
which is further decreased during LTP [102]. Increased neuronal activity also triggers the 
phosphorylation of proteasomes by calcium/calmodulin dependent kinase II [103]. These 
studies suggest neuronal proteasomes are regulated in very specific manners, and there 
may be many additional regulatory points remaining to be discovered. 
      Originally, the proteasome composition was investigated by column chromatography 
purifications, which tend to strip away the more loosely associated proteins. What 
remained were the core subunits of the proteasome complex. More recently, using 
affinity purifications under gentle conditions, many more interacting proteins have been 
identified on the proteasome. We may think of proteasome subunits as proteins strongly 
bound to the proteasome in stoichiometric amounts, and proteasome-interacting proteins 
as loosely bound proteins in sub-stoichiometric amounts. The subunits of the 20S 
proteasomes include α1–α7 (outer ring) and β1–β7 (inner ring). The 19S consists of as 
ATPase-subunits (Rpt1–6) and non-ATPase subunits (Rpn1–3, 5–12) (see Fig. 2-2). 
     Several recent studies have characterized 26S proteasome interactors from different 
cell types using affinity purification and tandem mass spectrometry [104-106]. The 
surprising finding is that the complement of proteasome interactors differs very 
significantly from one cell type to another. This implies that the each type of cell has a 
different proteome, and thus requires different proteasome interactors to facilitate 
different proteolytic tasks. For instance, muscle proteasomes are associated with many 
myofibrillar proteins and metabolic enzymes. This may be related to the role of 
proteasome in rapidly degrading muscle fibers during starvation [104]. This prompts us 
to investigate whether the spectrum of proteasome interactors in neurons is also different 
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from other cells, and how neuronal proteasomes may be regulated to meet the neuron’s 
specialized proteolytic demands.  
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Chapter 3 
 
 Composition of neuronal proteasomes 
 
 
 
 
 
 
 
 
 
 
 
3.1   Introduction 
      A cell may contain several forms of proteasomal complexes, including doubly and 
singly capped 26S, free 20S, and free 19S (Fig. 2-2). The first goal of this study is to 
understand the distribution of these proteasome species in the brain. Moreover, each of 
these proteasomes species may be associated with a significant number of proteins. 
Because 26S proteasomes are responsible for degrading ubiquitinated proteins, this study 
is focused on characterizing their interacting proteins and regulation. Recently, Besche et 
al. have described an affinity purification method that allows for the gentle, rapid 
isolation of 26S proteasomes together with associated proteins [104]. This approach is 
based upon the high affinity of 26S proteasomes for the UBL domain of Rad23B [107] 
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and a competitive elution strategy (Fig. 3-1). Through a collaboration with the Goldberg 
group at Harvard Medical School, I have utilized this newly developed method to purify 
26S proteasomes from the adult rat cortex. In particular, 26S proteasomes were 
successfully purified from biochemically isolated cytosolic and synaptosomal fractions of 
the cortex. The spectrum of 26S interactors in the cytosol and the synapse were 
determined by tandem mass spectrometry, and interesting differences were observed. 
Altogether, brain 26S interactors significantly differ from those found in other 
mammalian cells [104, 105].  
 
 
Aga-GSH
GST-UBL
26S
UIM-His
Ni-NTA  
Figure 3-1. Affinity purification of 26S proteasomes. The proteasome is captured using 
the ubiquitin-like (UBL) domain of Rad23B fused to glutathione-S-transferase (GST) 
over a matrix of glutathione-agarose (GSH-Aga). Proteasomes are eluted with the 
ubiquitin-interacting motif (UIM) tagged with polyhistidine. The UIM is taken from the 
Rpn10 subunit of the proteasome and competes for the UBL. His-UIM can be 
subsequently removed by absorption to Ni2+-nitrilotriacetic (Ni-NTA) resin. This yields 
highly purified 26S proteasomes devoid of GST-UBL or His-UIM contamination.  
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3.2   Neurons are enriched in doubly-capped 26S proteasomes 
     Since very little is known about the proteasome content of the brain, we first 
investigated what types of proteasomes may exist in the adult rat cortex. Using native gel 
electrophoresis followed by immunoblotting against 19S and 20S subunits, we found 
doubly capped 26S, singly capped 26S, and 20S proteasome in rat cortical extracts (Fig. 
3-2a); their relative abundance is quantified and summarized in Fig. 3-2b. Interestingly, 
the ratio of doubly over singly capped 26S proteasome was higher in the cortex than in 
liver and the kidney. Additionally, we detected free 19S particles in these cell types, as 
well as a subcomplex containing the 19S subunit Rpt1 (Fig. 3-2a). My collaborators in 
Harvard have characterized this complex from liver extracts by tandem mass 
spectrometry (LC-MS/MS) and found S5b, Rpn1, Rpt1, and Rpt2 (Henrike Besche, 
personal communication), recently shown to be an intermediate of 19S assembly [108-
113]. It should be noted that the resolution of the native gel electrophoresis likely 
underrepresents the actual heterogeneity of various proteasome species in vivo. For 
instance, some 20S particle might be associated with the PA28 complex (and other 
proteins), but these interesting proteins may dissociate readily or fail to alter mobility 
under these gel conditions. Also, it has been previously observed that a single proteasome 
band in the native gel can in fact contain diverse interacting proteins in substoichiometric 
amounts [104]. 
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Figure 3-2. (A) Proteasome species found in different cell types. Extracts of HeLa cell 
(30 μg), rat cortex (60 μg), rat liver (40 μg), and rat kidney (50 μg) were resolved by 2–
5% gradient native gel, immunoblotted against 19S subunit Rpt1, and reprobed against 
20S subunit α7. Protein bands were pseudo-colored and merged to illustrate the presence 
of proteasomes and related species (from top to bottom): doubly-capped 26S 
proteasome, singly-capped 26S proteasome, free 19S particle and free 20S particle. A 
fast-migrating band corresponding to a subcomplex of the 19S containing Rpt1 protein 
was also observed. 19S complex is schematically represented by a green semicircle; 20S 
complex by a red rectangle. (B) The distribution of different proteasome species in (A), 
quantified by densitometry (mean ± SEM, n=6) 
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3.3   Proteasome integrity after subcellular fractionation 
       In order to understand the role of the UPP in synaptic function and plasticity, I 
investigated the properties of synaptic proteasomes (outlined in Fig 3-3a). Slight 
modifications of standard protocols for isolating cytosolic and synaptosomal fraction 
were sufficient to preserve proteasome integrity, as assessed by native gel electrophoresis 
(Fig. 3-3b) and activity assays (Fig. 3-4). When cytosolic and synaptosomal extracts were 
incubated with glutathione S-transferase (GST)-UBL and glutathione sepharose, the 
flow-through fraction was depleted of 19S-subunit Rpt1 protein (Fig. 3-3c). Thus GST-
UBL affinity capture provides an efficient method to purify the entire population of 26S 
proteasomes, without apparent bias towards a specific subset. By contrast, there was a 
high amount of α7 subunit remaining in the flow through (Fig. 3-3c), which was 
consistent with the abundance of free 20S particles (which lack affinity for ubiquitin or 
UBL-proteins) detected in the native gel (Fig. 3-3b). Also, when GST-alone was used, 
instead of GST-UBL, no proteasome or other complexes were detectable (Fig. 3-5a). 
These experiments were carried out in the absence of salt to maximize the content of 
proteasome-associated proteins [104].  
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Figure 3-3. (A) Steps used in purification of cytosolic and synaptic 26S proteasomes, 
and subsequent analysis by gel electrophoresis and mass spectrometry (MS). (B) 
Proteasome integrity after subcellular fractionation. Cytosolic (Cyt) and synaptic (Syn) 
extracts prepared from rat cortices were resolved by 2%–5% gradient native gel, 
immunoblotted against 19S subunit Rpt1, and reprobed for 20S subunit α7. Singly-, 
doubly-capped 26S, 20S proteasomes and free 19S were detected in both fractions. (C) 
Efficacy of 26S proteasome isolation by UBL column. Cytosolic (Cyt) and synaptic 
(Syn) extracts were incubated with GST-UBL and glutathione sepharose. The input (IN) 
and flow-through (FT) materials were analyzed by SDS-PAGE and immunoblotted 
against Rpt1 and α7. The depletion of Rpt1 from the flow-through indicated that most 
26S proteasomes remained intact during subcellular fractionation and were captured 
with high efficiency. The high remaining level of α7 subunit in the flow through is 
consistent with the abundance of free 20S particles detected in (B). 
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Figure 3-4. Cytosolic and synaptosomal extracts 
contain active 26S proteasomes. Cytosolic (Cyt) and 
synaptic (Syn) extracts isolated from rat cortices were 
resolved by 2%–5% gradient native gel, followed by 
incubation with Suc-LLVY-AMC, a fluorogenic 
proteasome substrate. Active 26S proteasomes appear 
as fluorescent bands.   
 
 
3.4   Purification of cytosolic and synaptic proteasomes 
      Using the GST-UBL/His-UIM method, cytosolic and synaptic 26S proteasomes were 
successfully purified. When resolved by native gel electrophoresis and silver stained, 
each proteasome sample showed only two prominent bands, corresponding to doubly and 
singly capped 26S proteasomes (Fig. 3-5a). The identities of proteasome-related bands 
were confirmed by immunoblotting with antibodies against 19S and 20S subunits (Fig. 3-
6). By sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
silver staining, cytosolic and synaptic 26S proteasomes showed differences in associated 
proteins, and very few proteins were found in GST controls (Fig. 3-5b). Purified 26S 
proteasomes from both compartments remained active in hydrolyzing fluorogenic peptide 
substrates (Fig. 3-5c). Interestingly, the ratio of doubly over singly capped 26S was 
significantly higher in the cytosol than in the synapse (Fig. 3-5d).  Taken together, the 
data demonstrates that the distribution of proteasome species varies between different 
cells and tissues as well as between different subcellular compartments of the brain.  
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Figure 3-5. (A) Purity of isolated 26S proteasomes. Cytosolic (Cyt) and synaptic (Syn) 
26S proteasomes were isolated using GST-UBL/His-UIM. In control (Con) 
experiments, GST was added instead of GST-UBL. Samples were resolved by 3%-8% 
gradient native gel and silver-stained. (B) The same samples in (A) analyzed by SDS–
PAGE, followed by silver staining. The control experiments showed only a few non-
specific protein bands. (C) Activity of isolated proteasomes. Chymotrypsin-like 
peptidase activity of isolated 26S proteasomes resolved by 3–8% native gel was 
assayed with Suc-LLVY-AMC. (D) Differences in capped proteasome ratios. Silver-
stained 26S proteasome bands in (C) were quantified by densitometry. The ratio of 
doubly- over singly-capped 26S was significantly higher in the cytosol (Cyt) than the 
synaptosome (Syn) (mean ± SEM, n=4, *p<0.05). 
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Figure 3-6.  Purified 26S 
proteasomes contain both singly- and 
doubly-capped species. Isolated 
cytosolic 26S proteasomes resolved 
by native gel were silver-stained and 
immunoblotted against 19S subunit 
Rpt1 and 20S subunit α7 (top panel). 
Assuming the 19S:20S ratio in the 
lower band to be 1:1, band intensities 
on Western blots are plotted in the 
lower panel and quantified (see 
numbers in the top panel). The top 
band has a 19S:20S ratio close to 2:1 
(1.143:0.504). Therefore, the upper 
band represents 19S-20S-19S 
(doubly-capped 26S) and the lower 
band represents 19S-20S (singly-
capped 26S).   
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3.5   Identification of 26S proteasome-interacting proteins 
      To determine the identity of proteins that co-purified with 26S proteasomes, the 
samples were digested with trypsin and the resulting peptides were analyzed by mass 
spectrometry. Protein matches from the GST alone sample, which must represent non-
specific contaminants that interact with the matrix, were subtracted from protein matches 
in the GST-UBL sample. The remaining bound proteins represented either stoichiometric 
proteasome subunits (α1-7, β1-7, Rpt1-6, Rpn1-3, and Rpn5-12, see Table 3-2) or 
putative 26S proteasome-interacting proteins (listed in Table 3-1). Included in this latter 
group were several E3s, DUBs, molecular chaperones, and components of the UPP. 
During the purification, the majority of ubiquitylated substrates associated with 26S 
proteasomes were removed because they became bound to His-UIM proteins on Ni-NTA 
resins, as previously reported [104]. Consequently, ubiquitin or ubiquitin conjugate 
substrates were not detectable in purified 26S samples. Proteins listed in Table 3-1 
therefore most likely represent true proteasome-interacting proteins, not transiently 
associated proteasome substrates. Many of these proteins have previously also been 
reported to interact with proteasomes from non-neuronal cells [99, 104-106, 114]. 
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Table 3-1. Mass spectrometric identification of proteins that  
co-purify with cytosolic and synaptic 26S proteasomes 
 
 
IPI identifier 
Unigene 
identifier 
Gene name 
Gene 
symbol 
Cytosolic 26S Synaptic 26S 
    
Unique 
peptidesa 
Sequence 
coverage 
Unique 
peptidesa 
Sequence 
coverage 
Substoichiometric proteasome protein 
IPI00367234.3 Rn.154631 
Proteasome-associated protein 
ECM29 
Ecm29 6 5% 0 0% 
IPI00204510.5 Rn.9320 
26S proteasome subunit Rpn13/ 
ADRM1 
Adrm1 3 6% 3 6% 
IPI00200601.2 Rn.40430 Thioredoxin-like protein 1/ TRP32 Txnl1 13 56% 14 60% 
19S assembly factor 
IPI00194471.1 Rn.13415 
26S proteasome non-ATPase 
subunit 5/ S5b 
Psmd5 14 38% 13 37% 
IPI00231038.4 Rn.24127 
26S proteasome non-ATPase 
subunit 9/ Bridge-1/ p27 
Psmd9 5 24% 5 24% 
E3 
IPI00201213.3 Rn.12130 
HECT, UBA and WWE domain 
containing 1/ ARF-BP1 
Huwe1 51 21% 54 21% 
IPI00365749.3 Rn.198497 
Isoform 2 of ubiquitin-protein 
ligase E3A/ E6-AP 
Ube3a 20 27% 16 24% 
IPI00768915.1 n/a 
Potassium channel modulatory 
factor 1 
Kcmf1 4 27% 4 23% 
DUB 
IPI00734588.1 Rn.40424 
Ubiquitin carboxyl-terminal 
hydrolase L5/ UCH37 
Uchl5 7 26% 5 23% 
IPI00207657.1 Rn.44078 
Ubiquitin specific protease 5/ 
isopeptidase T 
Usp5 33 46% 38 48% 
IPI00372303.3 Rn.72721 
Ubiquitin specific protease 7/ 
HAUSP 
Usp7 8 13% 12 17% 
IPI00367362.3 n/a Ubiquitin specific protease 13 Usp13 9 26% 8 24% 
IPI00204532.2 Rn.11790 Ubiquitin specific protease 14 Usp14 20 43% 17 37% 
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UPP         
IPI00382052.2 Rn.3474 
Isoform 2 of TAX1-binding protein 
1/ T6BP 
Tax1bp1 0 0% 3 6% 
IPI00194561.1 Rn.107103 Isoform 1 of sequestosome-1/ p62 Sqstm1 6 28% 5 17% 
N-end rule        
IPI00359416.3 Rn.37755 
Retinoblastoma protein associated 
factor p600/ RBAF600/ UBR4 
Ubr4 66 18% 74 19% 
VCP complex        
IPI00212014.2 Rn.98891 Valosin-containing protein/ p97 Vcp 18 28% 30 41% 
IPI00204786.1 Rn.203087 Fas-associated factor 1 Faf1 11 23% 11 21% 
Chaperone        
IPI00207355.3 Rn.211303 Heat shock-related 70 kDa protein 2 Hspa2 4 9% 4 9% 
Vesicle         
IPI00204644.1 Rn.107689 
 Isoform B of synaptosomal-
associated protein 25  
Snap25 0 0% 11 50% 
IPI00394488.2 Rn.203179 
Glioblastoma amplified sequence/ 
NIPSNAP2 
Gbas 6 31% 6 26% 
Cytoskeleton        
IPI00231407.4 Rn.11247 Isoform A of drebrin Dbn1 0 0% 1 4% 
IPI00197579.1 Rn.2458 Isoform 1 of tubulin beta 5 Tubb5 5 17% 4 15% 
IPI00195673.1 Rn.98430 Tubulin beta 6 Tubb6 4 13% 3 10% 
Calcium binding  
IPI00231771.4 Rn.8937 Protein S100-b S100b 1 16% 1 16% 
Phosphopeptide binding 
IPI00230835.4 Rn.29936 14-3-3 protein gamma Ywhag 0 0% 1 6% 
IPI00324893.4 Rn.1292 14-3-3 protein zeta/delta Ywhaz 1 6% 1 6% 
RASGEF        
IPI00200118.4 Rn.53868 
Isoform 2 of GRIP1-associated 
protein 1/ GRASP-1 
Gripap1 0 0% 1 2% 
Unknown        
IPI00362402.3 n/a 
Alpha/beta hydrolase domain 
containing 10 
Abhd10 0 0% 1 3% 
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IPI00188755.4 Rn.106046 
Caspase recruitment domain-
containing protein 
C10orf97 4 12% 4 14% 
Clathrin complexb 
IPI00193983.1 Rn.3589 Clathrin heavy chain Cltc 0 0% 12 11% 
IPI00203346.4 n/a AP-2 complex subunit alpha-1 Ap2a1 0 0% 1 2% 
IPI00471901.3 Rn.34928 AP-2 complex subunit alpha-2 Ap2a2 0 0% 3 6% 
IPI00231502.3 Rn.56138 
Isoform 2 of AP-2 complex subunit 
beta-1 
Ap2b1 0 0% 2 2% 
IPI00196530.1 Rn.3172 AP-2 complex subunit mu-1 Ap2m1 0 0% 2 6% 
IPI00358691.2 Rn.162085 
Epidermal growth factor receptor 
pathway substrate 15 isoform B 
Eps15 0 0% 3 6% 
Mitochondriac 
IPI00196750.1 Rn.106922 
Single-stranded DNA-binding 
protein, mitochondrial  
Ssbp1 0 0% 4 40% 
 
 
 
Note: a uniqueness is defined solely by peptide sequence. b The clathrin complex appears 
to directly bind to GST-UBL independent of proteasome. c Mitochondrial proteins may be 
contaminants of synaptosomes.  
 
39 
 
 
 
Table 3-2.  26S proteasome subunits identified by mass spectrometry 
 
 
IPI identifier 
Unigene 
identifier 
Gene name 
Gene 
symbol 
Cytosolic 26S Synaptic 26S 
    
Unique 
peptides 
Sequence 
coverage 
Unique 
peptides 
Sequence 
coverage 
20S particle        
IPI00191501.1 Rn.107278 
Proteasome subunit alpha 
type 6 (α1)  
Psma6 6 27% 7 31% 
IPI00231757.11 n/a 
Proteasome subunit alpha 
type 2 (α2) 
Psma2 8 44% 10 50% 
IPI00231046.8 Rn.11076 
Proteasome subunit alpha 
type 4 (α3) 
Psma4 5 21% 6 16% 
IPI00215243.3 Rn.105784 
Isoform RC6-IL of 
proteasome subunit alpha 
type 7 ( α4) 
Psma7 11 46% 12 44% 
IPI00191502.5 Rn.1276 
Proteasome subunit alpha 
type 5 (α5) 
Psma5 7 30% 7 30% 
IPI00191748.3 Rn.2668 
Proteasome subunit alpha 
type 1 (α6) 
Psma1 13 55% 13 52% 
IPI00476178.2 Rn.3997 
Proteasome subunit alpha 
type 3 (α7) 
Psma3 6 28% 6 25% 
IPI00188686.2 n/a 
Proteasome subunit beta type 
6 (β1) 
Psmb6 4 29% 4 29% 
IPI00199980.1 Rn.3846 
Proteasome subunit beta type 
7 precursor (β2) 
Psmb7 4 16% 4 16% 
IPI00214889.1 Rn.94551 
Proteasome subunit beta type 
3 (β3) 
Psmb3 5 33% 5 33% 
IPI00188584.1 Rn.1981 
Proteasome subunit beta type 
2 (β4) 
Psmb2 10 56% 6 41% 
IPI00230992.5 n/a 
Proteasome subunit beta type 
5 (β5)  
Psmb5 12 49% 12 51% 
IPI00191749.5 Rn.6016 
Proteasome subunit beta type 
1 precursor (β6) 
Psmb1 7 40% 6 33% 
IPI00191505.3 Rn.6169 
Proteasome subunit beta type 
4 precursor (β7) 
Psmb4 8 43% 8 43% 
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19S particle        
IPI00421600.7 Rn.1202 
26S proteasome ATPase 
subunit 2 (Rpt1) 
Psmc2 29 55% 28 52% 
IPI00211733.1 Rn.10526 
26S proteasome ATPase 
subunit 1 (Rpt2) 
Psmc1 24 55% 23 55% 
IPI00210158.1 Rn.11341 
26S proteasome ATPase 
subunit 4 (Rpt3) 
Psmc4 21 55% 26 70% 
IPI00362105.2 Rn.103233 
26S proteasome ATPase 
subunit 6 (Rpt4) 
Psmc6 18 53% 18 50% 
IPI00190392.3 Rn.11173 
26S proteasome ATPase 
subunit 3 (Rpt5) 
Psmc3 27 63% 25 56% 
IPI00213587.1 Rn.10972 
26S proteasome ATPase 
subunit 5 (Rpt6) 
Psmc5 24 52% 24 55% 
IPI00370456.1 Rn.29909 
26S proteasome non-ATPase 
subunit 2 (Rpn1) 
Psmd2 40 46% 39 46% 
IPI00212512.1 Rn.2891 
26S proteasome non-ATPase 
subunit 1 (Rpn2) 
Psmd1 31 37% 29 41% 
IPI00370009.1 Rn.101332 
26S proteasome non-ATPase 
subunit 3 (Rpn3) 
Psmd3 31 48% 33 54% 
IPI00198978.1 Rn.15873 
26S proteasome non-ATPase 
subunit 12 (Rpn5) 
Psmd12 27 50% 28 50% 
IPI00370382.2 n/a 
26S proteasome non-ATPase 
subunit 11 (Rpn6) 
Psmd11 29 55% 27 56% 
IPI00189463.1 Rn.103875 
26S proteasome non-ATPase 
subunit 6 (Rpn7) 
Psmd6 21 44% 20 39% 
IPI00359611.2 Rn.20659 
26S proteasome non-ATPase 
subunit 7 (Rpn8) 
Psmd7 12 47% 11 46% 
IPI00202283.1 Rn.16918 
26S proteasome non-ATPase 
subunit 13 (Rpn9) 
Psmd13 20 56% 21 58% 
IPI00372125.3 Rn.161794 
26S proteasome non-ATPase 
subunit 14 (Rpn11) 
Psmd14 13 46% 14 53% 
IPI00364072.1 Rn.137673 
26S proteasome non-ATPase 
subunit 8 (Rpn12) 
Psmd8 7 19% 6 19% 
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3.6   Confirmation of proteasome-interacting proteins  
     As it is also possible that a protein can interact directly with the UBL domain of 
hHR23B (without association with the 26 proteasome), we confirmed the proteasome 
association of several proteins listed in Table 3-1 by co-sedimentation, which is 
independent of the GST-UBL interaction. When cytosolic and synaptic extracts were 
subjected to centrifugation at 100,000xg for 6 hr, 20S and 26S proteasomes were largely 
found in the pellet fraction (Fig. 3-7). Under this condition, proteasome-interacting 
proteins identified by mass spectrometry should co-sediment with the proteasome. A total 
of 7 putative proteasome-interacting proteins were examined, including three ubiquitin 
ligases HUWE1 (HECT, UBA and WWE domain containing 1), E6-AP (E6-associated 
protein; UBE3A), and KCMF1 (potassium channel modulatory factor 1); USP14 
(ubiquitin-specific protease 14, a DUB); PSMD9 (also called p27/Bridge-1), a recently 
identified 19S assembly factor [108, 109, 113]; ECM29, the only proteasome protein 
detected exclusively in the cytosol in this study; and 14-3-3γ, which recognizes 
phosphopeptides and was found only in synaptic proteasomes.   
        Thus, all proteins tested co-sedimented with the proteasome in the subcellular 
compartment predicted from the mass spectrometry data (Fig. 3-7). In summary, among 
the 30 26S-associated proteins identified as listed in Table 1, most were found in both 
compartments, but only ECM29 was cytosol-specific, and 6 proteins were synaptosome-
specific, although four of them could be identified by MS with one unique peptide only.  
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Figure 3-7. Verification of proteasome-
interacting proteins. Cytosolic (Cyt) and 
synaptosomal (Syn) extracts of rat cortices 
were subjected to centrifugation at 
100,000xg for 6 hr. The supernatant (Sup) 
and pellet materials (Pel) were loaded at 
1:1 ratio and resolved by SDS-PAGE. The 
sedimentation of proteasomes was 
confirmed by the high levels of 20S 
subunit α7 and 19S subunit Rpt1 in the 
pellet fraction. Proteins identified by mass 
spectrometry in 26S proteasomes (26S 
MS) from the cytosol and the synaptosome 
are indicated by the positive sign. 
Agreement between mass spectrometry 
data and co-sedimentation data was 
observed for all seven 26S-interacting 
proteins (UBE3A, HUWE1, KCMF1, 
USP14, PSMD9, ECM29, 14-3-3γ) probed 
by specific antibodies (see methods). 
Parkin and PI31 did not show appreciable 
association with proteasomes.  
 
 
     In summary, the co-sedimentation data showed very good agreement with the mass 
spectrometry data to validate our fractionation and purification strategy. It is noteworthy 
that we could not detect by mass spectrometry parkin (an E3 mutated in autosomal-
recessive juvenile Parkinsonism) and PI31 (which may function as an inhibitor of the 20S 
proteasome), which have been reported as proteasome-interacting proteins in non-
neuronal cells [115, 116]. Also, neither co-sedimented with proteasomes (Fig. 3-7).  
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      In addition, clathrin and several of its interactors involved in vesicular trafficking 
were isolated (Table 3-1). This complex was found to bind the UBL-domain 
independently of the proteasome in purifications from synaptosomes and microsomes in 
our preliminary experiments. In this study, ultracentrifugation (1 hr at 100,000xg) before 
UBL-purification efficiently removed this complex; however, traces were still detectable 
by LC-MS/MS. Whether the clathrin complex can interact with proteasomes remains to 
be determined. 
      Another potential concern we had was whether UBL was directly binding to the VCP 
complex, which contains many factors that can bind to ubiquitin [117]. When proteins 
captured by GST-UBL affinity capture were immunoblotted against VCP, no signal could 
be detected (Fig. 3-8). This indicates that, unlike in muscle extracts [104], VCP 
complexes did not appear to independently bind the UBL domain. We currently cannot 
explain this difference. Phosphatase inhibitors used in this purification might reduce the 
binding of VCP complexes to the UBL domain as previously described [104]. In some of 
the preliminary experiments I performed at the Goldberg lab in Harvard, it appeared that 
the purification procedure of GST-UBL may also affect its affinity for the VCP complex, 
but this was not further investigated.   
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Figure 3-8. VCP is not captured by GST-UBL 
affinity chromatography. 26S proteasomes from 
the cytosolic (Cyt) and synaptic (Syn) extracts 
were purified by the GST-UBL/His-UIM method. 
The input (IN) material and eluted (EL) fraction 
containing purified 26S proteasomes were 
analyzed by SDS-PAGE and immunoblotted 
against VCP, 19S subunit Rpt1, and 20S subunit 
α7. The levels of VCP that co-purified with 26S 
proteasomes were below the limit of Western blot 
detection. 
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3.7   Discussions 
 
26S proteasome-interacting proteins have diverse functions  
        26S proteasome-interacting proteins identified from the rat cortex have diverse 
cellular roles (Table 3-1). The presence of 3 E3s (KCMF1, HUWE1, and UBE3A) and 5 
DUBs (USP5, USP7, USP13, USP14, and UCH37/UCH-L5) is especially significant 
because they may edit ubiquitin chains or determine substrate selectivity at the 
proteasome. Some interactors appear to bring substrates to the proteasome by binding to 
ubiquitylated proteins (Tax1BP1, p62/sequestosome 1)  [118, 119] or N-end rule proteins 
(UBR4/RBAF600) [120]. A heat shock protein 70 family chaperone, HSPA2, may help 
unfold proteins [121]. The valosin-containing protein (VCP)/p97 complex can bind 
ubiquitylated proteins and also act as a chaperone [117, 122]. Another interactor, 
thioredoxin-like 1/TRP32, a disulfide reductase with induced expression upon oxidative 
stress [123], was recently implicated in transferring nascent chain substrates to the 
proteasome via a mechanism that involves eEF1A1 [124]. As our purification method 
utilized RAD23B’s UBL domain, RAD23B and related substrate shuttling factors such as 
ubiquilin 1 [125] were expectedly absent in the interactors we found. 
      Some of the interactors have been reported as factors that help stabilize or assemble 
proteasomes, including ECM29 [126, 127], PSMD9 [108, 113, 128], and S5b [110, 112]. 
The presence of signal transduction proteins may help proteasomes respond to signaling 
events in the neuron. These include S100B, a small calcium-binding protein [129], and 
14-3-3, which recognizes phosphoproteins [130]. Another category of interactors appears 
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to localize proteasomes to appropriate subcellular structures or locations. These include 
cytoskeleton proteins (drebrin and tubulin) and the synaptic vesicle protein SNAP-25.  
     Comparing the spectrum of 26S-interacting proteins from muscle cells, HEK293 cells, 
and neurons, we find that there are significant differences (smaller than 50% overlap 
between any two of them). It is not yet understood how proteasome composition is 
regulated in different cells, which may be an important future direction.  
 
Properties of synaptic proteasomes 
       There is growing evidence that proteasome-mediated proteolysis plays a critical role 
in synaptic plasticity (recently reviewed in [12, 14]). We still know relatively little, 
however, about the proteins targeted for degradation or the molecular mechanisms 
involved. Although several studies have examined ubiquitin ligases involved in synaptic 
function [14], a major gap in our knowledge concerns the nature of the proteasome in the 
central nervous system and in different neuronal compartments. In this study, we used a 
new isolation method and mass spectrometry to characterize the synaptic and cytosolic 
26S proteasomes and their interactors, and on this basis examined activity-induced 
proteasome changes. Several differences were found between synaptic and cytosolic 26S 
particles. For example, we found a lower ratio of doubly to singly capped 26S 
proteasomes in the synapse than in the cytosol. ECM29, which strengthens the 
association of 19S and 20S particles [126, 127], was present in the cytosolic 26S but not 
the in the synaptic 26S, which may contribute to the high amount of doubly capped 26S 
in the cytosol. The functional differences between doubly and singly capped 26S have not 
been established. Both forms can degrade ubiquitylated proteins [131], and thus it is 
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possible that the doubly capped form has twice the capacity to bind and degrade 
substrates. On the other hand, the singly capped 26S has an exposed 20S α-ring that 
allows it to interact with additional regulators such as PA28 or PA200 [27]. Such 
interacting proteins may dissociate during native gel electrophoresis. Consequently, the 
singly-capped species seen here may in fact represent in vivo hybrid particles, 19S-20S-X, 
where X could be PA28, PA200, or unknown factors.  
     Several proteasome-interacting proteins identified are unique to the synaptic 26S 
proteasome (14-3-3γ, TAX1BP1, drebrin, SNAP-25) and provide new insights. 14-3-3γ, 
which recognizes phosphopeptides [130], may coordinate proteasome function with 
protein phosphorylation events that regulate synaptic transmission [132]. TAX1BP1 is a 
ubiquitin-binding protein [118, 133] that may promote substrate-proteasome association 
at the synapse. It will be interesting to examine which synaptic proteins interact with 
TAX1BP1. Previous studies suggested that proteasomes are sequestered in dendritic 
spines by interacting with the actin cytoskeleton [25]. Our data suggests that the 
interaction may be partially mediated by drebrin, an important actin-binding protein in 
the spine [134]. At the presynaptic terminal, proteasome-mediated proteolysis can 
regulate synaptic vesicle release in several ways [48, 49]. We found synaptic proteasomes 
interact with SNAP-25, a key synaptic vesicle protein [135, 136], which may provide a 
mechanism for the proteolytic control of vesicle dynamics.  
      Although cytosolic and synaptic 26S proteasomes interact with many similar proteins 
(Table 3-1), their properties and functions may differ at the synapse. For example, here 
we confirm the presence of USP14 on synaptic proteasomes by both affinity co-
purification and co-sedimentation. It is noteworthy that the current model for ataxia (axJ) 
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mice is that the loss of USP14 from synaptic proteasomes may lead to enhanced 
proteolysis, as occurs in yeast lacking the homologous DUB [114]. Usp14 has a long and 
a short splicing isoform in mouse brain, and the latter lacks the N-terminal UBL domain 
necessary for proteasome binding. In fact, axJ mice arise from spontaneous mutations in 
the loss of the long isoform, accompanied by altered synaptic activity and movement 
defects [137, 138].  
 
Synaptic proteasomes and receptor endocytosis 
      Regulating the surface level of receptors and channels is a key mechanism in synaptic 
plasticity [61, 132]. There is increasing evidence that one of the major functions of 
synaptic proteasomes is to facilitate the endocytosis of receptors and channels (reviewed 
in [13, 14]), and most likely proteins interacting with synaptic 26S proteasomes 
contribute to this process.  
     When neurons are exposed to high concentrations of glutamate or NMDA, glutamate 
receptors are rapidly endocytosed [59, 60]. Two studies have shown that the endocytosis 
of glutamate receptors requires proteasome activity [55, 57]. The key proteolytic targets 
are likely to be the PSD scaffolding proteins that help anchor receptors, including Shank, 
GKAP, GRIP1, and AKAP79/150 [51, 56, 57, 102]. Glutamate receptors released from 
the PSD are then internalized at the lateral zone of the spine [58]. As discussed earlier, 
under these circumstances, 26S proteasomes are recruited into dendritic spines [25], but 
the ligases that are co-recruited to help determine substrate selectivity are not known. 
Here we identified multiple E3s and DUBs that associate with both cytosolic and 
synaptic 26S proteasomes, which may co-migrate with proteasomes to PSD sites. Most, 
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but not all of these DUBs and ligases are also found on 26S from skeletal muscles [104]. 
These proteasome-associated DUBs presumably function together with Rpn11 subunit (a 
different type of DUB) to catalyze the disassembly of the ubiquitin chain to allow the 
degradation of the protein substrate [139]. Exactly why so many different 
deubiquitylating activities are required at this step is unclear. Also quite mysterious is 
why these particular ligases are associated directly with the proteasome since hundreds of 
other E3s also exist in mammals and the great majority appear to function without 
association with the 26S. Which postsynaptic proteins are targeted by proteasome-
associated E3s and DUBs also remain to be elucidated. The PSD is a large assembly of 
densely packed proteins [50] and once some PSD scaffolding proteins are ubiquitylated, 
it is not clear how the proteins dissociate from the PSD for degradation by the 
proteasome. Among the chaperones we found in synaptic 26S proteasomes, the VCP 
complex may assist this process, because it is a powerful chaperone and also binds to 
polyubiquitylated proteins [117]. 
    Some proteasome interactors may help localize the proteasome to endocytic substrates. 
Sequestosome 1/p62 can bind to the GluR1 subunit of α-amino-3-hydroxy-5-methyl-4-
isoazolepropionate (AMPA) receptor, D2 dopamine receptor, type C gamma-
aminobutyric acid (GABAC) receptor, and potassium channel subunit Kvβ2 [140]. 
Similarly, TAX1BP1 has been shown to bind GABAC receptors [141]. Because p62 and 
TAX1BP1 also bind to ubiquitylated substrates, we propose that they may recruit the 
proteasome to facilitate the UPP-dependent endocytosis of receptors and channels.  
     Based on the proteomic characterization of synaptic 26S proteasomes, we may put 
forth a tentative model for how 26S interactors facilitate the degradation of PSD proteins 
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(Fig. 3-9). Currently, the function of most 26S interacting proteins remains 
uncharacterized, and this model may serve as a starting point for future studies. 
 
 
 
(I)  Association with receptors:
p62
(II) Ubiquitination, chain editting
KCMF1, HUWE1, UBE3A (E3)
USP5, 7, 13, 14, UCH37 (DUB)
(III) Recognition of ubiquinatedproteins
TAX1BP1, p62
VCP, FAF-1 (chaperone complex)
(IV) Regulation of proteasome
S100B (calcium binding)
14-3-3γ (recognize phosphoproteins)
Thioredoxin like -1 (redox)
(V)  Association with local structure
drebrin (cytoskeleton)
PSMD9 (PDZ domain)
red = synapse-specific interactor  
Figure 3-9. A hypothetical model for how proteasome interactors participate in the 
degradation of PSD proteins. Here, proteasome interactors are divided into functional 
categories with different roles in proteolysis. However, we know very little about their 
actual function at the synaptic 26S proteasome.  
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3.8   Experimental methods 
Reagents 
       Antibodies against the following antigens were purchased commercially: α7 
(PW8110), Rpt1 (PW8825), UBE3A (PW0535), ubiquitin conjugates (UG9510), PI31 
(PW9710) from Biomol/Enzo (Plymouth Meeting, PA); ECM29 (PA3-035), USP14 
(MA1-57109), PA28α (PA1-960) from Affinity Bioreagents/Thermo (Rockford, IL); 
parkin (MAB5512), ubiquitin monomer (MAB1510) from Chemicon/Millipore (Billerica, 
MA); PSMD9 (sc-10670), 14-3-3γ (sc-731) from Santa Cruz Biotechnology (Santa Cruz, 
CA); HUWE1 (A300-486A) from Bethyl (Montgomery, TX); tubulin β3 (T8860) from 
Sigma (St Louis, MO); KCMF1 (15-288-21213) from Genway (San Diego, CA). Nonidet 
P-40 (NP-40) was purchased from BDH (Poole, England). Protease inhibitor cocktail 
(complete, EDTA-free) was purchased from Roche (Indianapolis, IN). Phosphatase 
inhibitor (cocktail 2) and chloroquine were purchased from Sigma. Epoxomicin was 
purchased from Biomol and EMD  Bioscience (Gibbstown, NJ). 
 
Recombinant protein purification 
     GST-UBL and His-UIM plasmids and their expression in bacteria have been 
previously described [104]. Cells expressing GST-UBL were lysed by sonication in 
phosphate buffered saline, and purified using glutathione sepharose 4B (GE Healthcare, 
Piscataway, NJ). Cells expressing His-UIM were lysed by B-PER extraction reagent 
(Pierce/Thermo), and purified using Ni-NTA resin (Qiagen, Valencia, CA). Detailed 
procedures are described below: 
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       pDEST-15-HHR23BUBL plasmid  was transformed into BL21AI (Invitrogen) 
according to manufacturer’s instructions. Cells were grown at 37 oC with ampicillin to an 
OD600 of 0.5 and induced for 3 hr with 1 g/L L-arabinose. Cell pellet from 1 L culture 
was resuspended in 100 mL ice-cold phosphate buffered saline (PBS, 10 mM Na2HPO4, 
1.8 mM KH2PO4, 2.7 mL KCl, 137 mM NaCl, pH 7.4) with 2mM DTT, 10 mM MgCl2, 
0.2 mg/mL lysozyme and protease inhibitors (complete, Roche). The entire purification 
procedure was carried out at 4 oC. Cells were lysed by sonication, and the cell debris was 
removed by centrifugation at 20,000xg for 30 min. The supernatant was passed through 
0.2 μm filters and supplemented with 0.2% Triton X-100, followed by incubation with 20 
mL of glutathione sepharose for 2 hr. The resin was transferred to a gravity-flow column, 
and washed several times in PBS with 0.2% Triton X-100. GST-UBL was eluted by 
adding 50 mL of elution buffer (75 mM Tris pH 8.8, 150 mM NaCl, 40 mM reduced 
glutathione), and the collected fractions were combined and dialyzed against buffer B (25 
mM HEPES pH 7.5, 10% glycerol, 5 mM MgCl2 1 mM DTT). Small aliquots of 10 
mg/mL GST-UBL were frozen in liquid nitrogen and stored at -80 oC. The final yield 
from 1L culture was ~100 mg.  
          pET26b-S5aUIM2 plasmid was transformed into BL21 (DE3) (Promega) according 
to manufacturer’s instructions. Cells were grown at 37 oC with kanamycin to an OD600 of 
0.8, followed by induction with 0.5 mM IPTG for 2 hr at 30 oC. Cell pellet from 1 L 
culture (~20 mg of His-UIM) was resuspended in 30 mL B-PER extraction reagent 
(Pierce/Thermo) supplemented with 3 mM 2-mercaptoethanol and DNase I (Sigma). 
After 15 min of extraction at 25 oC with mixing, the lysate was cooled to 4 oC and 
centrifuged at 20,000xg for 20 min. The supernatant was passed through 0.2 μm filters, 
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supplemented with 10 mM imidazole, and incubated with 10 mL of Ni-NTA for 1 hr. The 
resin was transferred to a gravity-flow column and washed first with a 1:1 mixture of B-
PER and wash buffer (50 mM Tris pH 7.5, 40 mM imidazole, 300 mM NaCl), and then 
just wash buffer. 20 mL of elution buffer (50mM Tris pH 7.5, 250 mM imidazole, 300 
mM NaCl) was added, and collected fractions containing His-UIM were combined and 
dialyzed against buffer B with 40 mM KCl. Protein concentration was compared to 
bovine serum albumin standards (Pierce/Thermo) using two gel-staining methods: 
Coomassie blue and E-Zinc stain (Pierce/Thermo). Small aliquots of 2 mg/mL His-UIM 
were frozen in liquid nitrogen and stored at -80 oC.  
Neuronal cultures and tissues 
       Cortex, liver, and kidney were dissected from 4–6 weeks old male Sprague-Dawley 
rats. Dissociated hippocampal neurons were prepared and maintained as previously 
described [142]. Briefly, hippocampi from postnatal day 0 to 2 rats were dissected out 
and dissociated by papain and plated at a density of 70,000 cells/cm2 onto poly-D-lysine-
coated 60 mm culture dishes (Falcon). Cultures were maintained in neuronal growth 
medium, which is Neurobasal A medium containing B-27 and Glutamax supplements 
(Invitrogen), at 37 oC for 21–28 days before use. Tissue extracts were prepared in buffer 
A (20 mM HEPES, 0.32 M sucrose, 5 mM MgCl2, 2 mM ATP, 2 mM DTT, protease and 
phosphatase inhibitors, pH 7.2) with 0.2% NP-40, using motor-driven Potter-Elvehjem 
homogenizers. Extracts of cultured neurons were prepared in buffer A with 0.5% NP-40, 
using glass dounce homogenizers. Extracts were cleared by centrifugation at 18,000xg 
for 15 min to remove nuclei and cell debris, and protein concentrations were measured by 
Coomassie Plus protein assay (Pierce).  
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Neuronal treatment 
     Prior to NMDA stimulation, conditioned medium was collected from neuronal culture 
dishes. Neuronal growth media containing 20 μM NMDA was added to the culture for 3 
min, followed by two washes with HEPES buffered saline (20 mM HEPES pH 7.4, 119 
mM NaCl, 5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 30 mM glucose). After the second 
wash, conditioned medium was added to the culture.  
Synaptosome isolation 
      Adult rat cortices rapidly frozen in liquid nitrogen and stored at -80 oC were used for 
isolating synaptosomes, based on standard protocols [143] with buffer modifications to 
stabilize proteasomes. The procedure is schematically represented in Fig. 3-10. Briefly, 
cortices from 4 rats were homogenized in a motor-driven Potter-Elvehjem homogenizer 
in 30 mL buffer A (20 mM HEPES, 0.32 M sucrose, 5 mM MgCl2, 2 mM ATP, 2 mM 
DTT, protease and phosphatase inhibitors, pH 7.2). The homogenate was centrifuged at 
1000xg for 5 min, and the supernatant was collected as S1 (if cloudy, centrifuged one 
more time). S1 was centrifuged at 12,000xg for 20 min, and the pellet (P12) was 
resuspended in buffer A and centrifuged again at 12,000xg for 20 min. The synaptosome 
pellet (P12’) was resuspended in 11 mL buffer A with 1% NP-40 using a Potter-Elvehjem 
homogenizer to disrupt the vesicles and extract proteins. This was followed by 
centrifugation at 18,000xg for 10 min, and then at 100,000xg for 1 hr to sediment clathrin 
complexes and debris. The supernatant (S100) was collected as synaptosomal extract. To 
collect the cytosolic extract, supernatant S12 was centrifuged at 100,000xg to remove 
microsomes. The supernatant was collected as cytosolic extract and supplemented with 
1% NP-40. Synaptosomal protein yield from 4 cortices was ~50 mg.  
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Proteasome capture and sedimentation 
      GST-UBL was added to cell extracts (50 µg/1 mg of total protein) and incubated with 
glutathione sepharose to capture and deplete 26S proteasomes. To sediment proteasomes, 
cell extracts were pre-cleared at 100,000xg for 1 hr, followed by centrifugation at 
100,000xg for 6 hr. Pellets were redissolved in 50 mM Tris pH 7.5, 6M urea, and 1% 
SDS.  
Proteasome activity assay 
        26S proteasome activity in cell extracts was measured by a proteasome activity kit 
(Biomol/Enzo) and a fluorometer, based on the hydrolysis of Suc-LLVY-AMC, a 
fluorogenic substrate for chymotrypsin-like peptidase activity. Native gels containing 26S 
proteasomes were incubated with reaction buffer (50 mM Tris pH 7.5, 10 mM MgCl2, 1 
mM ATP, 1 mM DTT, 50 μM Suc-LLVY-AMC) for 30 min at 37 oC.  
Affinity purification of 26S proteasomes 
      From cytosolic and synaptosomal extracts (both in buffer A with 1% NP-40), 26S 
proteasomes were isolated using the GST-UBL/His-UIM method essentially as 
previously described [104]. The purification was conducted at 4 oC. First, cytosolic or 
synaptosomal extracts (20 mg total protein) were incubated for 2 hr with 1 mg GST-UBL 
and 200 μL glutathione sepharose 4B. After transferring to a gravity-glow column, resins 
were washed with 20 mL buffer A plus 0.5% NP-40, followed by 30 mL of buffer B plus 
1 mM ATP and 5 mM MgCl2. Proteasomes were eluted by a 20 min incubation with 250 
μL His-UIM (2 mg/mL, with 2 mM ATP), and repeated one more time. The combined 
eluate was incubated with 120 μ Ni-NTA for 20 min, and passed through 0.22 µm spin-
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filters (ultrafree MC, Millipore). The filtrate contained purified 26S proteasomes. For 
control samples, 0.7 mg GST was substituted for GST-UBL in the purification procedure.  
Immunoblotting and silver staining.  
       PVDF membranes with transferred proteins were blocked with 5% non-fat milk in 50 
mM Tris pH 7.5, 150 mM NaCl, and 0.05% Tween-20. Primary antibodies and HRP-
conjugated secondary antibodies were applied in blocking reagent, followed by standard 
chemiluminescence detection. Band intensities on scanned films were quantified by 
densitometry using the gel analysis function in ImageJ software. Silver staining was 
performed with SilverSNAP kit II (Pierce/Thermo).  
Native gel electrophoresis 
     To resolve proteasomes from cell extracts, 2–5% gradient native gels were prepared 
using the mini-protean 3 system and acrylamide/Bis (37.5:1) from Bio-Rad. The gel 
formulation was modified from published protocols for discontinuous native gels [144] 
based on Tris-borate-EDTA buffer (TBE, 90 mM Tris base, 80 mM boric acid, 0.1 mM 
EDTA, pH 8.3). Each 1.5 mm, 10-well gradient gel was made by mixing 3.3 mL of the 
upper gel solution (70 mM Tris pH 6.8, 2% acrylamide, 0.06% APS, 0.12% TEMED) 
and 6.3 mL of lower gel solution (1X TBE, 5% acrylamide, 3.5% sucrose, 1 mM DTT, 1 
mM ATP, 5 mM MgCl2, 0.05% APS, 0.1% TEMED). Samples were mixed with 4X 
loading buffer (100 mM Tris pH 8.0, 20% glycerol) just before loading. Electrophoresis 
was carried out at 6–10 oC, in TBE running buffer (with 0.5 mM DTT, 0.5 mM ATP and 
2 mM MgCl2). The applied voltage was gradually increased with time (30V for 30 min, 
35V for 1 hr, 50 V for 1 hr, 65V for 2–4 hr). To resolve isolated 26S proteasomes, 1.5 
mm, 10-well 3–8% Tri-acetate gels (Invitrogen) were used. Gel loading buffer and 
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running buffer were the same as above. Electrophoresis was carried out at 4 oC and 150 V 
for 4 hr.   
      For immunoblotting, proteins in native gels were transferred to PVDF membranes 
using Bio-Rad mini-protean 3 transfer system (buffer contains 25 mM Tris base, 192 mM 
glycine, 0.1% SDS) for 4 hr at 70 V (current limit: 350 mA) in a 4 oC room. Fluorescent 
bands around 26S proteasomes were visualized and quantified by standard gel-imaging 
systems for DNA staining by ethidium bromide.    
 
Mass spectrometry.  
      Mass spectrometric analysis of purified proteasomes was performed with the 
generous support of Dr. Wilhelm Haas and Dr. Steven Gygi at Harvard Medical School. 
Proteasome samples were sent to the Gygi lab, where they were digested with trypsin and 
the generated peptides were subjected to nanoscale-microcapillary reversed phase liquid 
chromatography tandem mass spectrometry (LC-MS/MS) using an in-house packed C18 
125 µm I.D. capillary column and a hybrid linear ion trap/FT-ICR mass spectrometer 
(LTQ FT, Thermo  Electron, Bremen, Germany) as described previously [145]. Using the 
SEQUEST algorithm, MS/MS data were searched against a concatenated target-decoy 
database created based on the rat IPI protein database including sequences of known 
contaminant proteins. Search results were filtered to a protein false discovery rate of less 
than 1% [146]. Data shown in Table 3-1 and 3-2 were compiled from two independent 
experiments, and each experiment used four rats to prepare brain homogenates.  
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Figure 3-10.  A schematic showing the preparation of synaptosomal and cytosolic extracts 
from rat cortices. We include an additional centrifugation step (1 hr, 100,000xg) after 
solubilization of synaptosomes with NP-40 and before incubation with the UBL domain. 
Solubilization leads to binding of an unrelated clathrin complex to the UBL matrix, which 
complicates the mass spectrometric analysis (data not shown). The respective 
centrifugation step removes the bulk of this clathrin complex while the proteasome 
remains fully soluble. 
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Chapter 4 
 
Proteasome composition is  
regulated by synaptic activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1   Introduction 
      Studies from non-neuronal cells have suggested that the proteasome complex is 
highly plastic and subject to many forms of regulation [98]. In neurons, several forms of 
synaptic plasticity have been shown to require UPP activity [46, 147]. We are therefore 
interested in understanding how neuronal activity regulates the UPP. Our lab has 
previously shown that, when neuronal activity is stimulated by depolarization, 
proteasomes are recruited to dendritic spines to facilitate the endocytosis of glutamate 
receptors [25, 55, 56]. Hence, protein ubiquitination is not the only aspect of the UPP 
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regulated by neuronal activity. This chapter further examines whether proteasome levels 
and compositions are regulated by neuronal activity. 
 
4.2   26S proteasomes decrease after NMDA exposure 
     A prior study showed that several minutes of neuronal stimulation by KCl or NMDA 
enhanced the subsequent degradation of a model UPP substrate in dendrites and caused 
26S proteasomes to enter dendritic spines within minutes [25]. Therefore we examined 
whether proteasome levels and proteasome-interacting proteins are regulated by similar 
activities. In this experiment, cultured rat hippocampal neurons were stimulated with 20 
μM NMDA for 3 min, a common protocol for the pharmacological induction of long-
term plasticity (chemical LTD) [148]. Due to low synaptosome yields from neuronal 
cultures, it was not possible to perform subcellular fractionation, and instead we analyzed 
total extracts at 30 min and 4 hr post-NMDA treatment for changes in proteasome 
properties.  
     To our surprise, the greatest changes in neuronal proteasome occurred at 4 hr post-
treatment. At this time point, 26S proteasome levels determined by native gel 
electrophoresis (Fig. 4-1a) showed a significant decrease (25±3%, p<0.05). At the same 
time, levels of the free 19S and the 19S precursor (Rpt1-subcomplex) decreased similarly, 
and free 20S levels increased by 30±5% (p<0.05), while the total 20S level (26S+free 
20S) remained constant when compared to untreated controls (Fig. 4-1c). This result is 
consistent with the disassembly of 26S proteasomes into 20S and 19S particles. However, 
free 20S particles increased but free 19S particles decreased, suggesting the disassembly 
of the 19S particle.  
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     Next, we asked if the subunits of the disassembled 19S particles became free proteins 
or became degraded. At 4 hr post-NMDA, we did not detect free subunits of the 19S in 
the neuronal extract using the proteasome sedimentation assay. In the sedimentation 
experiment, free subunits of the 19S should remain in the supernatant instead of 
precipitating into the pellet, but no 19S protein was detectable in the supernatant (Fig. 4-
3a). On the other hand, the total 19S level in the neuronal extract decreased by 33±4% 
(Fig. 4-1b and 4-1d). Thus, the data suggests that 19S particles dissociated from 20S 
particles eventually became degraded, resulting in an observed shift from 26S 
proteasomes to free 20S proteasomes.  
          To our knowledge, this is the first report of 19S catabolism in mammalian cells and 
therefore its molecular mechanism remains unclear. To examine if 19S degradation 
occurs through a UPP- or lysosome-dependent proteolysis, proteasome inhibitor 
epoxomicin and lysosome inhibitor chloroquine were applied shortly after NMDA was 
washed out (Fig. 4-2). Surprisingly, neither inhibitor was able to block 19S degradation. 
There are several possible explanations for this result. First, 19S degradation may occur 
in a proteasome- and lysosome-independent manner, and additional proteolytic 
mechanisms may be involved. Secondly, both the proteasome and the lysosome may be 
able to degrade 19S components and the cell is able to compensate when either pathway 
is blocked. Third, the inhibitor may be applied too late to affect 19S catabolism.  
Additional experiments will be required to resolve these possibilities.   
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Figure 4-1. (A) Neuronal proteasome profile changes induced by NMDA treatment. 
Cultured hippocampal neurons were treated with 20 μM NMDA for 3 min, and total cell 
extracts were prepared at 30 min or 4 hr post-treatment. Untreated control (Con) and 
treated samples were resolved by 2–5% gradient native gel and immunoblotted against 
20S subunit α7 and 19S subunit Rpt1. (B) Extracts from (A) resolved by SDS-PAGE 
and probed for total levels of α7, Rpt1, and VCP, an abundant UPP protein. Tubulin 
served as the loading control. (C) Quantification of changes in proteasome profile in (A) 
by densitometry (n=6, mean ± SEM, *p<0.05). (D) Quantitation of the result in (B) by 
densitometry. 19S subunit Rpt1 shows significant decrease at 4 hr post-NMDA (n=6, 
*p<0.05). 
 
63 
 
 
 
 
 
Figure 4-2. 19S degradation is not blocked by proteasome or lysosome inhibitors. (A) 
Pharmacological treatment of cultured neurons. Cells were treated with 20 μM 
NMDA, 1 μM proteasome inhibitor epoxomicin (Epo), 0.1 mM lysosome inhibitor 
chloroquine (Chl), or vehicle (Veh) as indicated. (B) Whole-cell lysates of treated 
neurons were immunoblotted for 20S subunit α7 and 19S subunit Rpt1. Tubulin 
served as loading control. (C) Total 19S levels quantified by densitometry. (n=4, mean 
± SEM, *p<0.05 by paired t-test). Epoxomicin and chloroquine do not prevent 
NMDA-induced 19S degradation. (D) Total 20S levels quantified by densitometry 
(mean ± SEM , n=4). NMDA does not induce 20S degradation. 
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4.3   NMDA exposure affects proteasome-bound E3s 
     Next, we examined if proteasome-interacting E3s and DUBs were co-degraded with 
the 19S. While ubiquitin ligases HUWE1 and UBE3A showed significant degradation at 
4 hr post-NMDA, the ligase KCMF1 and the DUB enzyme USP14 remained unchanged 
(Fig. 4-3a and 4-3b). We estimated the degree of HUWE1 and UBE3A’s association with 
proteasomes after NMDA stimulation by co-sedimentation experiments (100,000xg, 6 hr) 
(Fig. 4-3c). At 4 hr post-NMDA, the fraction of HUWE1 and UBE3A in the proteasome 
pellet was lower than untreated controls (Fig. 4-3d), suggesting that the subpopulation of 
HUWE1 and UBE3A associated with proteasomes was more sensitive to degradation 
than the unbound pool. In contrast, neither KCMF1 protein levels nor its association with 
the proteasome were significantly affected by NMDA exposure (Fig. 4-3b and 4-3d). The 
data also imply that different E3s may be associated with different subpopulations of 
proteasomes, because not all E3s are equally affected by 26S disassembly and 19S 
degradation.  
     The apparent shift from 26S from 20S proteasomes has two potential outcomes: one is 
reduced capacity for ubiquitin- and 26S-dependent proteolysis, and the other is increased 
capacity for ubiquitin-independent, 20S-dependent proteolysis. It has been reported that 
20S proteasomes can degrade oxidized proteins independent of ubiquitination [149, 150]. 
Therefore, we also examined the interactors of 20S proteasomes after NMDA stimulation. 
After the increase in 20S levels, 20S-interactors such as proteasome activator PA28α and 
proteasome inhibitor PI31 did not show increased association with 20S proteasomes (Fig. 
4-3d). It is still unclear if the newly released 20S proteasomes from the disassembled 26S 
proteasomes are proteolytically active. 
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Figure 4-3. (A) NMDA induces the degradation of proteasome-interacting E3s. Cultured 
hippocampal neurons were treated with 20 μM NMDA for 3 min, and total cell extracts 
were prepared at 30 min or 4 hr post-treatment. Control (Con) and treated samples were 
resolved by SDS-PAGE and immunoblotted against proteasome-interacting E3s 
(HUWE1, UBE3A, KCMF1) and DUB (USP14). (B) Signal intensities in (A) are 
normalized against 20S subunit α7 and plotted (n=5, mean ± SEM, *p<0.05). (C) 
Changes in the proteasome-association of E3s. Neuronal extracts from (A) were 
subjected to ultracentrifugation to sediment proteasomes. Equal amounts of supernatant 
(Sup) and pellet (Pel) materials were analyzed. The sedimentation property of 
proteasome-interacting proteins (HUWE1, UBE3A, KCMF1, PA28α) was examined by 
Western blotting. Parkin and PI31 were not detected in the pellet. (D) Quantitation of the 
fraction of proteins in (C) that co-sediment with proteasomes (n=4, *p<0.05) 
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4.4    NMDA exposure alters proteasome activity and ubiquitin levels 
       Because 26S levels decreased at 4 hr post-NMDA, we also measured if there were 
corresponding changes in 26S activity based on the hydrolysis of Suc-LLVY-AMC, a 
proteasome substrate. In a gel-based assay, the activity of the NMDA-treated samples 
was found to be reduced relative to controls (68±6%, p<0.05) (Fig. 4-4a and b). Peptidase 
assays conducted on neuronal extracts also showed reduced activity in the NMDA-treated 
samples when compared to controls (73±4%, p<0.05) (Fig. 4-4b). The degree of 
peptidase activity decrease was comparable to the observed decrease in 26S levels 
(75±3%) (Fig. 4-1b).  
     Decreases in 26S proteasome activity could lead to the accumulation of ubiquitin-
protein conjugates, if there were no global changes in the rate of ubiquitylation and 
deubiquitylation. While ubiquitin-protein conjugate levels in NMDA-treated neurons 
showed no change at 30 min post-treatment, a significant decrease was observed at 4 hr 
(68±10%, p<0.05) (Fig. 4-4c and d). The simultaneous and similar decrease in 26S 
proteasome levels, 26S proteasome activity, and steady-state ubiquitin-conjugate levels at 
4 hr post-NMDA suggests a coordinated reduction in the rate of proteolysis mediated by 
the 26S proteasome, but the fall in ubiquitin conjugates strongly suggest that protein 
ubiquitylation also decreased.   
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Figure 4-4. (A) Decreases in proteasome activity after NMDA exposure. Neuronal lysates 
were prepared at 30 min or 4 hr post-NMDA (20 μM, 3 min). Control (Con) and treated 
samples were resolved by 2–5% gradient native gel. In-gel 26S proteasome activity was 
detected by the hydrolysis of proteasome substrate Suc-LLVY-AMC. (B) 26S proteasome 
activity per mg of total protein after NMDA treatment measured by two assays. The first 
assay measured fluorescent signals shown in (A). In the second assay, Suc-LLVY-AMC 
was added to the cell extract, and the fluorescence increase was measured over time to 
calculate 26S proteasome activity (mean ± SEM, n=5, *p<0.05). (C) Levels of ubiquitin 
conjugates after NMDA treatment. Neuronal extracts from (A) were resolved by SDS-
PAGE and blotted using antibodies against ubiquitin-protein conjugates (Ub conj) and 
free monomeric ubiquitin (free Ub). Tubulin served as the loading control. (D) Signals in 
(C) quantified by densitometry. Ubiquitin-protein conjugates showed significant 
decreases at 4 hr post-NMDA treatment (n=5, *p<0.05). 
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4.5   Discussions 
 
Long-lasting changes in proteasome levels 
         In this study, 3 min of neuronal stimulation by 20 μM NMDA application was 
found to elicit profound changes in the proteasome complex several hours later. How 
does a brief episode of stimulation create such long-lasting changes in the UPP? It is well 
established that 3–5 min of 20–50 μM NMDA application causes LTD in CA1 
hippocampal neurons and in cultured hippocampal neurons [148, 151] by triggering the 
internalization of glutamate receptors. This can be considered as a homeostatic 
mechanism to reduce synaptic transmission after the neuron sense excessive NMDA 
receptor activity.  
        Our data suggests that prolonged depression in neuronal activity following LTD 
induction is accompanied by prolonged decreases in UPP activity. This is consistent with 
a recent report showing that action potential blockade with tetrodotoxin causes a decrease 
in dendritic proteasome activity, while prolonged stimulation with bicuculline causes 
increased proteasome activity, as monitored by the degradation of fluorescent model 
substrates [103]. It appears that lowering neuronal activity also lowers its requirement for 
UPP activity.  
     In yeast, it has been observed that prolonged down-regulation of UPP activity is 
accompanied by the gradual dissociation of 26S proteasomes into 19S and 20S particles 
[152]. Our data suggests that, in neurons, the down-regulation of UPP following NMDA-
induced LTD also leads to 26S disassembly. This is followed by the degradation of the 
dissociated 19S particles, as well as the degradation of proteasome-bound E3 ligases, 
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HUWE1 and UBE3A. This type of delayed response to a brief period of neuronal 
stimulation may be relevant to the establishment or maintenance of long-term synaptic 
plasticity and learning. Intriguingly, HUWE1 mutations in humans cause X-linked mental 
retardation [85], and UBE3A mutations cause Angelman syndrome, characterized by 
mental retardation, developmental delay, and jerky movement [153]. Most HUWE1 
proteins at the synapse, but not the cytosol, appear to be proteasome-bound (Fig. 3-7). 
Hence, the synaptic function of HUWE1 appears to be mostly proteasome-dependent. 
UBE3A has been shown to impair LTP and alter spine morphology [154, 155], which 
may explain why Angelman syndrome patients develop cognitive problems. UBE3A is 
localized to dendrites and spines [155], and moreover our data suggests that it is partially 
associated with synaptic proteasomes. Little is known about how HUWE1 and UBE3A 
contribute to synaptic plasticity and learning, and why their defects lead to mental 
retardation, and we propose that their interactions with synaptic proteasomes and their 
synaptic substrates may be important.  
     The mechanisms of activity-regulated proteasomal changes are largely unclear at this 
point, and they will need to be addressed by future experiments. First of all, it is not clear 
why the neuron lowers its 26S levels by 19S degradation after NMDA-induced LTD. It 
may be that neurons with lower levels of synaptic activity require less UPP activity, and 
therefore eliminate proteasomes that are in excess. It is also not clear how 19S particles 
become degraded, and to our knowledge 19S catabolism has never been characterized in 
eukaryotic cells. Another question is whether the degradation of 19S is triggered by 
NMDA receptor signaling or by the down-regulation of synaptic activity, or maybe both. 
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Whether other forms of LTD induction may similarly lead to the reduction of 19S 
particles should be tested. 
      
Proteasomes and neuronal maintenance 
       The global decrease in 26S proteasome levels observed after NMDA treatment is in 
fact very surprising, when we consider the important role of the UPP in neuronal protein 
quality control. Unlike most cells, neurons cannot dispose of damaged proteins by cell 
division [156], and therefore must have evolved very stringent mechanisms to protect 
themselves from abnormal protein. In this context, we may consider how proteasome-
interacting proteins may be involved in neuronal protein quality control. 
     The thirty or so 26S-associated proteins we found in rat cortex differ considerably 
from those identified by the same approach in rat muscle (62 in total) [104]. In fact, only 
13 of the interactors are shared between the two cell types, even though myocytes are 
postmitotic just like neurons. Protein degradation serves distinct roles in neurons and 
skeletal muscles, which represent the major amino acid reservoir in mammals. Muscle 
proteins are mobilized (unlike those in neurons) through accelerated proteolysis in fasting 
or other stressful conditions [157]. Also, the protein composition in skeletal muscles and 
neurons is very different, which may necessitate the involvement of different factors to 
assist proteasome-mediated degradation. Whether such differences in the spectrum of 
proteasome-associated proteins exist between different brain regions remain to be 
explored. 
     The hallmarks of neurodegenerative disorders in general are neuronal inclusions of 
misfolded proteins, which often contain ubiquitylated proteins and proteasomes [65, 74]. 
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Therefore, factors that help deliver ubiquitylated proteins to proteasomes or facilitate 
their degradation are likely to be important in preventing protein aggregates or inclusions 
[12, 67, 97]. In cytosolic 26S proteasomes of the cortex, we identified two factors that 
seem to be important in reducing the accumulation of such aberrant proteins—the VCP 
complex and p62. Recently, VCP mutations were discovered in patients with inclusion 
body myopathy associated with Paget's disease of bone and frontotemporal dementia 
(IBMPFD) [158]. IBMPFD patients show degenerating neurons with inclusions of 
ubiquitylated TAR DNA binding protein (TDP-43) [159]. The cause of TDP-43 
aggregation is not yet clear, but current models suggest that it is related to a failure in the 
VCP to facilitate the degradation of TDP-43 [78, 160]. Our isolation of VCP and 
proteasome together from the cortex is consistent with such a role.     
      TDP-43 inclusions are also found in sporadic forms of amyotrophic lateral sclerosis 
and frontotemporal lobar degeneration [161]. It has been proposed that TDP-43, tau, and 
α-synuclein aggregates in sporadic neurodegenerative disorders are caused by the 
impairment of UPP-mediated proteolysis or the dysfunction of 26S proteasomes [74, 97]. 
Testing this hypothesis in humans or animals has proven difficult [77] in the past due to 
difficulties in isolation of 26S proteasome in their native forms. The affinity purification 
methods used here should greatly facilitate such studies.  
       Interestingly, mice deficient in p62 develop neurodegeneration with ubiquitylated, 
hyperphosphorylated tau inclusions [162]. This is thought to be related to p62’s role in 
targeting misfolded protein to the proteasome [36] as well as to autophagy [119]. In mice 
with brain region-specific knockout of a 19S subunit, neurodegeneration is accompanied 
by accumulation of ubiquitylated α-synuclein inclusions, reminiscent of human PD and 
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DLB [95]. These mice have decreased neuronal 26S levels with increases in 20S levels. 
In the present study, we observed a similar decrease in 26S content and increase in 
neuronal 20S proteasome through 19S dissociation and degradation. These observations 
highlight that many interesting possibilities for regulating neuronal proteasomes remain 
to be explored, and such regulations may have important effects on synaptic plasticity 
and protein quality control.  
 
Substrate delivery pathways to the proteasome 
      It is very curious that the abnormalities of just there proteins, α-synuclein, tau, and 
TDP-43, appear to be associated with 80–90% of neurodegenerative dementias [68, 69]. 
Furthermore, these aggregate proteins often appear together in late-stage dementia 
patients, a phenomenon termed co-morbidity [163]. Therefore, it might be possible to 
find a unifying principle or mechanism to explain why these proteins are observed in so 
many neurodegenerative disorders. Some propose that UPP dysfunction may be a 
common link between the deposition of different protein inclusions [164]. The data 
presented in this study appears to support to this idea, by highlighting the potential 
importance of delivering of ubiquitinated substrates to the proteasome.  
     It is known that there are multiple mechanisms to bring together the proteasome and 
its substrates, and our data provides insights into which of these mechanisms may be 
important for the neuron. Among the cytosolic 26S interactors identified, we found two 
binding adaptors for polyubiquitinated substrates: p62 and the VCP complex. The 19S 
also has multiple subunits that bind to ubiquitinated substrates [165]. In addition, binding 
adaptors carrying UBL domains, including RAD23 and ubiquilin family proteins [125], 
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are potentially missing in this study because GST-UBL was used to purify proteasomes. 
As such, p62, VCP, UBL proteins, and the 19S represent different substrate delivery 
pathways to neuronal proteasome that may work independently or together. Importantly, 
the genetic inactivation of different delivery pathways is sufficient to cause different 
pathological inclusions commonly seen in dementia patients (p62→tau, VCP→TDP -43, 
19S→α-synuclein, as discussed earlier). This may also explain why degenerating neurons 
often show co-morbidity of several aggregates species in late-stage dementia. In 
unhealthy neurons, the UPP dysfunction may be so profound that multiple degradation 
pathways are impaired and therefore multiple aggregate types appear together. Hence, 
UPP dysfunction may be one of the unifying mechanisms of protein misfolding problems 
in neurons.  
      Although the discussion above implies that UPP dysfunction can be a direct cause of 
inclusion formation, what contributes to UPP dysfunction remains elusive. Moreover, the 
UPP involves many genes and its organization and properties can vary between different 
cell types. For instance, this study suggests that proteasome-interacting proteins can vary 
significantly. To further understand how UPP function is related to the etiology of 
neurodegeneration, we will need a much better understanding of how the UPP operates in 
neurons to degrade different types of proteins.    
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Chapter 5 
 
Conclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.1   General Discussion 
     The UPP plays two important roles in facilitating the unique functions of the neuron. 
First, its activity is regulated by synaptic plasticity and participates in the remodeling of 
synapses. Second, it protects the neuron against aberrant proteins, such as oxidized and 
misfolded proteins, and especially those known to form inclusions in neurodegenerative 
disorders. How the UPP accomplishes these tasks in neurons is poorly understood in 
terms of molecular mechanisms. This thesis study attempts to addresses this issue by 
characterizing the basic properties of the brain proteasome complex.    
     This study originated from the simple hypothesis that proteasomes in neurons have 
different compositions from those in other cells, which was based on the idea that the 
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unique morphology and physiology of neurons would require specialized proteolytic 
mechanisms. By combining a novel affinity purification strategy and subcellular 
fractionation, cytosolic and synaptic 26S proteasomes were successfully isolated from the 
rat cortex. Proteomic characterization of brain proteasomes by mass spectrometry 
revealed that the spectrum of interacting proteins is indeed very different from those in 
muscle or heterologous cells. Proteasome-interacting proteins in the synapse and the 
cytosol also differ somewhat. This suggests that the proteolytic machinery can be 
organized differently to meet the proteolytic requirement of a particular cell type and a 
particular compartment of the cell.  
     While it is known that neuronal activity can regulate the UPP to facilitate synaptic 
remodeling, relatively little is understood about its mechanisms. Previous studies have 
shown that synaptic activity can regulate proteasome activity in dendrites and dendritic 
spines through posttranslational modification and proteasome redistribution [25, 103]. 
This study shows that 26S proteasome levels and activity decrease after NMDA 
stimulation, due to the disassembly of the 26S and the degradation of 19S particles. 
Moreover, proteasome composition also changes, as observed in the dissociation of 
interacting proteins such as E3 enzymes HUWE1 and UBE3A.  
     Previously, it was generally assumed that UPP activity is mostly controlled at the level 
of ubiquitination, and the proteasome remains relatively unchanged and passively accepts 
ubiquitinated substrates. This study demonstrates that the neuron also regulates the 
proteasome complex to modulate UPP activity. In addition, ubiquitin ligases bound to the 
proteasome are also regulated in a dynamic manner.  
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        Some researchers believe that the gradual reduction of neuronal proteasomes with 
aging may lead to the build-up of misfolded proteins and hence neurodegeneration [100, 
166]. My data suggests that proteasome levels can also decrease quite rapidly after 
NMDA-induced chemical LTD. Does this decrease compromise the neuron’s capacity to 
handle misfolded proteins? We do not know yet, but this is particularly interesting in the 
context of Alzheimer’s disease. Studies have shown that amyloid β can disrupt glutamate 
uptake and enhance LTD induction [167]. It is possible that excessive LTD induction can 
lead to decreased proteasome levels and render the neuron more vulnerable to proteotoxic 
stresses such as tau aggregation. To understand why degenerating neurons are not 
properly protected against misfolded proteins, we will need to understand how 
proteasomes are normally regulated in both healthy and stressed neurons. Although this 
study is the first to characterize neuronal proteasomes in detail, more questions seem to 
be raised than answered from such an initial effort. 
 
5.2   Future directions 
    The study described in this thesis lays an important foundation for future studies of 
neuronal proteasomes. First, it defines the basic composition of brain proteasomes, which 
is different from other tissues. Secondly, it shows that neuronal proteasome is 
dynamically regulated at multiple levels by synaptic activity. However, due to the 
complexity of the proteasome, our understanding of its actual heterogeneity and 
dynamics is still very limited.  
    The actual heterogeneity of neuronal proteasomes cannot be fully revealed by the 
experimental methods used in this study. It is unlikely for dozens of interacting proteins 
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to be present on the same proteasome. Proteasome heterogeneity represents a major 
obstacle when we try to determine how individual substrates are processed by the 
proteasome, and this needs be addressed in the future. It may be possible to use 
immunoprecipitation against different proteasome interactors to differentiate between 
different subpopulations of proteasomes.   
      Although this study observed a number of interesting proteasome alterations after 
NMDA treatment, the molecular mechanisms of such changes are unclear. More 
pharmacological experiments will be needed to dissect the signaling pathway that leads to 
proteasome alterations. We may expect posttranslational modifications of proteasome 
subunits and interacting proteins to play important roles in proteasome modulation. In the 
past, in vitro proteolysis experiments using purified proteasomes have proven to be 
challenging for many substrates. It would be interesting to see if affinity purified 
proteasomes containing many more auxiliary factors will be more potent for in vitro 
proteolysis. The ability to recreate proteasome degradation events in vitro will be very 
useful for deciphering the molecular steps involved.  
     While protein aggregation is the most prominent and the most common feature of 
neurodegeneration, very little is known about how neurons handle toxic proteins liked 
misfolded or oxidized proteins. In fact, the degradation of misfolded and oxidized 
proteins is poorly understood in all eukaryotic cells. To understand these processes in the 
neuron, we must additionally consider the fact that the proteolytic machinery in the 
neuron differs from other cell types. The brain represents only 2% of the body weight but 
uses 20% of the oxygen, mostly consumed by neurons. Thus, postmitotic neurons must 
have evolved efficient mechanisms to deal with protein oxidation. The proteasome is 
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generally considered as the first line of defense against misfolded and oxidized proteins 
[149, 150], followed by the lysosome. However, how misfolded proteins and oxidized 
protein are recognized and delivered to the proteasome remains largely unclear. We may 
expect at least some of the brain proteasome interacting proteins to serve a function in 
these processes, but the details remain elusive. The experimental approaches developed 
in this study may be applied to elucidate proteasome changes when neurons are 
challenged with misfolded proteins or oxidized proteins. For instance, we can transiently 
turn on the overexpression of a polyQ protein in mice brain, and purify brain proteasomes 
to see what interactors have changed due to the overexpression. This may give us some 
clues to which interacting protein may help proteasomes handle polyQ substrates. The 
same strategy can be applied to examine the proteasomal adaptations to oxidative stresses 
applied to neurons. Understanding how neurons handle oxidized and misfolded proteins 
may be help us elucidate the etiology of neuronal proteinopathies and find better 
treatments. 
       The dozens of proteasome interacting proteins identified in this study marks a major 
advance in our understanding of brain proteasomes. However, most of their functions at 
the proteasome are not known. This represents a new set of challenges to understand their 
functions and dynamics. The complexity of the proteasome is daunting because its 
composition varies from one tissue to another. To further address the heterogeneity of 
proteasomes may require future advances in proteomic mass spectrometry. The question 
of individual interactor function may depend on in vitro reconstitution experiments. 
Moreover, the very fundamental question of how a specific protein is catabolized in a cell 
has proven very difficult to investigate. Currently, most of the proteolysis inhibitors 
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available are very broad in their spectrum of action, such as blocking proteasomes, 
lysosomes, autophagy, or ubiquitination. What will be very useful are specific inhibitors 
against individual E2s, E3s or proteasome interacting proteins. 
     All in all, a deeper understanding of neuronal proteasomes is highly relevant to the 
study of synaptic plasticity and protein misfolding disorders in the brain, and needs to be 
furthere pursued. The proteasome has a central role in mediating the neuron’s proteomic 
changes and proteomic stability, but we are just beginning to unveil its complexity. 
Conceptually, enhancing proteasome function may help prevent proteinopathies in the 
brain. However, no pharmacological agent has been shown to enhance proteasome 
function in the cell, and this awaits future exploration.  
 
 
80 
 
 
 
References 
 
 
 
1. Morange, M. (2008). What history tells us XIII. Fifty years of the Central Dogma. 
J. Biosci. 33, 171-175. 
2. Schoenheimer, R. (1942). The Dynamic State of Body Constituents, (Cambridge, 
MA: Harvard UP). 
3. Simpson, M.V. (1953). The release of labeled amino acids from the proteins of rat 
liver slices. J. Biol. Chem. 201, 143-154. 
4. Ciechanover, A. (2005). Proteolysis: from the lysosome to ubiquitin and the 
proteasome. Nat. Rev. Mol. Cell. Biol. 6, 79-86. 
5. Goldberg, A.L. (2007). Functions of the proteasome: from protein degradation 
and immune surveillance to cancer therapy. Biochem. Soc. Trans. 35, 12-17. 
6. Ciechanover, A. (2006). Intracellular protein degradation: From a vague idea thru 
the lysosome and the ubiquitin-proteasome system and onto human diseases and 
drug targeting. Exp. Biol. Med. 231, 1197-1211. 
7. Hicke, L., and Dunn, R. (2003). Regulation of membrane protein transport by 
ubiquitin and ubiquitin-binding proteins. Annu. Rev. Cell Dev. Biol. 19, 141-172. 
8. Hershko, A., and Ciechanover, A. (1998). The ubiquitin system. Annu. Rev. 
Biochem. 67, 425-479. 
9. Belle, A., Tanay, A., Bitincka, L., Shamir, R., and O'Shea, E.K. (2006). 
Quantification of protein half-lives in the budding yeast proteome. Proc. Natl. 
Acad. Sci. USA 103, 13004-13009. 
10. Hirsch, C., Gauss, R., Horn, S.C., Neuber, O., and Sommer, T. (2009). The 
ubiquitylation machinery of the endoplasmic reticulum. Nature 458, 453-460. 
11. Steward, O., and Schuman, E.M. (2003). Compartmentalized synthesis and 
degradation of proteins in neurons. Neuron 40, 347-359. 
12. Tai, H.C., and Schuman, E.M. (2008). Ubiquitin, the proteasome and protein 
degradation in neuronal function and dysfunction. Nat. Rev. Neurosci. 9, 826-838. 
13. Bingol, B., and Schuman, E.M. (2005). Synaptic protein degradation by the 
ubiquitin proteasome system. Curr. Opin. Neurobiol. 15, 536-541. 
81 
 
 
 
14. Yi, J.J., and Ehlers, M.D. (2007). Emerging roles for ubiquitin and protein 
degradation in neuronal function. Pharmacol. Rev. 59, 14-39. 
15. DiAntonio, A., and Hicke, L. (2004). Ubiquitin-dependent regulation of the 
synapse. Annu. Rev. Neurosci. 27, 223-246. 
16. Murphey, R.K., and Godenschwege, T.A. (2002). New roles for ubiquitin in the 
assembly and function of neuronal circuits. Neuron 36, 5-8. 
17. Patrick, G.N. (2006). Synapse formation and plasticity: recent insights from the 
perspective of the ubiquitin proteasome system. Curr. Opin. Neurobiol. 16, 90-94. 
18. Macara, I.G., and Mili, S. (2008). Polarity and differential inheritance--universal 
attributes of life? Cell 135, 801-812. 
19. Kuhlbrodt, K., Mouysset, J., and Hoppe, T. (2005). Orchestra for assembly and 
fate of polyubiquitin chains. Essays Biochem. 41, 1-14. 
20. Peng, J.M., Schwartz, D., Elias, J.E., Thoreen, C.C., Cheng, D.M., Marsischky, G., 
Roelofs, J., Finley, D., and Gygi, S.P. (2003). A proteomics approach to 
understanding protein ubiquitination. Nat. Biotechnol. 21, 921-926. 
21. Xu, P., Duong, D.M., Seyfried, N.T., Cheng, D., Xie, Y., Robert, J., Rush, J., 
Hochstrasser, M., Finley, D., and Peng, J. (2009). Quantitative proteomics reveals 
the function of unconventional ubiquitin chains in proteasomal degradation. Cell 
137, 133-145. 
22. Semple, C.A.M. (2003). The comparative proteomics of ubiquitination in mouse. 
Genome Res. 13, 1389-1394. 
23. Ardley, H.C., and Robinson, P.A. (2005). E3 ubiquitin ligases. Essays Biochem. 
41, 15-30. 
24. Hartmann-Petersen, R., Seeger, M., and Gordon, C. (2003). Transferring 
substrates to the 26S proteasome. Trends Biochem. Sci. 28, 26-31. 
25. Bingol, B., and Schuman, E.M. (2006). Activity-dependent dynamics and 
sequestration of proteasomes in dendritic spines. Nature 441, 1144-1148. 
26. Dahlmann, B. (2005). Proteasomes. Essays Biochem. 41, 31-48. 
27. Rechsteiner, M., and Hill, C.P. (2005). Mobilizing the proteolytic machine: cell 
biological roles of proteasome activators and inhibitors. Trends Cell. Biol. 15, 27-
33. 
82 
 
 
 
28. Tanahashi, N., Murakami, Y., Minami, Y., Shimbara, N., Hendil, K.B., and 
Tanaka, K. (2000). Hybrid proteasomes: Induction by interferon-γ and 
contribution to ATP-dependent proteolysis. J. Biol. Chem. 275, 14336-14345. 
29. Luzio, J.P., Pryor, P.R., and Bright, N.A. (2007). Lysosomes: fusion and function. 
Nat. Rev. Mol. Cell. Biol. 8, 622-632. 
30. Mukhopadhyay, D., and Riezman, H. (2007). Proteasome-independent functions 
of ubiquitin in endocytosis and signaling. Science 315, 201-205. 
31. Gruenberg, J., and Stenmark, H. (2004). The biogenesis of multivesicular 
endosomes. Nat. Rev. Mol. Cell. Biol. 5, 317-323. 
32. Nixon, R.A., and Cataldo, A.M. (1995). The endosomal-lysosomal system of 
neurons: new roles. Trends Neurosci. 18, 489-496. 
33. Pillay, C.S., Elliott, E., and Dennison, C. (2002). Endolysosomal proteolysis and 
its regulation. Biochem. J. 363, 417-429. 
34. Dice, J.F. (2007). Chaperone-mediated autophagy. Autophagy 3, 295-299. 
35. Nakatogawa, H., Suzuki, K., Kamada, Y., and Ohsumi, Y. (2009). Dynamics and 
diversity in autophagy mechanisms: lessons from yeast. Nat. Rev. Mol. Cell. Biol. 
10, 458-467. 
36. Pankiv, S., Clausen, T.H., Lamark, T., Brech, A., Bruun, J.A., Outzen, H., 
Overvatn, A., Bjorkoy, G., and Johansen, T. (2007). p62/SQSTM1 binds directly 
to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by 
autophagy. J. Biol. Chem. 282, 24131-24145. 
37. Hebb, D.O. (1949). The Organization of Behavior: A Neuropsychological Theory, 
(New York: Wiley). 
38. Davis, H.P., and Squire, L.R. (1984). Protein synthesis and memory: a review. 
Psycho. Bull. 96, 518-559. 
39. Lopez-Salon, M., Alonso, M., Vianna, M.R.M., Viola, H., Souza, T.M.E., 
Izquierdo, I., Pasquini, J.M., and Medina, J.H. (2001). The ubiquitin-proteasome 
cascade is required for mammalian long-term memory formation. Eur. J. Neurosci. 
14, 1820-1826. 
40. Lee, S.H., Choi, J.H., Lee, N., Lee, H.R., Kim, J.I., Yu, N.K., Choi, S.L., Kim, H., 
and Kaang, B.K. (2008). Synaptic protein degradation underlies destabilization of 
retrieved fear memory. Science 319, 1253-1256. 
41. Hegde, A.N., Goldberg, A.L., and Schwartz, J.H. (1993). Regulatory subunits of 
cAMP-dependent protein kinase are degraded after conjugation to ubiquitin: a 
83 
 
 
 
molecular mechanism underlying long-term synaptic plasticity. Proc. Natl. Acad. 
Sci. USA 90, 7436-7440. 
42. Chain, D.G., Casadio, A., Schacher, S., Hegde, A.N., Valbrun, M., Yamamoto, N., 
Goldberg, A.L., Bartsch, D., Kandel, E.R., and Schwartz, J.H. (1999). 
Mechanisms for generating the autonomous cAMP-dependent protein kinase 
required for long-term facilitation in Aplysia. Neuron 22, 147-156. 
43. Hegde, A.N., Inokuchi, K., Pei, W., Casadio, A., Ghirardi, M., Chain, D.G., 
Martin, K.C., Kandel, E.R., and Schwartz, J.H. (1997). Ubiquitin C-terminal 
hydrolase is an immediate-early gene essential for long-term facilitation in 
Aplysia. Cell 89, 115-126. 
44. Zhao, Y.L., Hegde, A.N., and Martin, K.C. (2003). The ubiquitin proteasome 
system functions as an inhibitory constraint on synaptic strengthening. Curr. Biol. 
13, 887-898. 
45. Fonseca, R., Vabulas, R.M., Hartl, F.U., Bonhoeffer, T., and Nagerl, U.V. (2006). 
A balance of protein synthesis and proteasome-dependent degradation determines 
the maintenance of LTP. Neuron 52, 239-245. 
46. Karpova, A., Mikhaylova, M., Thomas, U., Knopfel, T., and Behnisch, T. (2006). 
Involvement of protein synthesis and degradation in long-term potentiation of 
Schaffer collateral CA1 synapses. J. Neurosci. 26, 4949-4955. 
47. Krug, M., Lossner, B., and Ott, T. (1984). Anisomycin blocks the late phase of 
long-term potentiation in the dentate gyrus of freely moving rats. Brain Res. Bull. 
13, 39-42. 
48. Willeumier, K., Pulst, S.M., and Schweizer, F.E. (2006). Proteasome inhibition 
triggers activity-dependent increase in the size of the recycling vesicle pool in 
cultured hippocampal neurons. J. Neurosci. 26, 11333-11341. 
49. Yao, I., Takagi, H., Ageta, H., Kahyo, T., Sato, S., Hatanaka, K., Fukuda, Y., 
Chiba, T., Morone, N., Yuasa, S., et al. (2007). SCRAPPER-dependent 
ubiquitination of active zone protein RIM1 regulates synaptic vesicle release. Cell 
130, 943-957. 
50. Sheng, M., and Hoogenraad, C.C. (2007). The postsynaptic architecture of 
excitatory synapses: a more quantitative view. Annu. Rev. Biochem. 76, 823-847. 
51. Ehlers, M.D. (2003). Activity level controls postsynaptic composition and 
signaling via the ubiquitin-proteasome system. Nat. Neurosci. 6, 231-242. 
52. Burbea, M., Dreier, L., Dittman, J.S., Grunwald, M.E., and Kaplan, J.M. (2002). 
Ubiquitin and AP180 regulate the abundance of GLR-1 glutamate receptors at 
postsynaptic elements in C. elegans. Neuron 35, 107-120. 
84 
 
 
 
53. Rezvani, K., Teng, Y., Shim, D., and De Biasi, M. (2007). Nicotine regulates 
multiple synaptic proteins by inhibiting proteasomal activity. J. Neurosci. 27, 
10508-10519. 
54. Kato, A., Rouach, N., Nicoll, R.A., and Bredt, D.S. (2005). Activity-dependent 
NMDA receptor degradation mediated by retrotranslocation and ubiquitination. 
Proc. Natl. Acad. Sci. USA 102, 5600-5605. 
55. Patrick, G.N., Bingol, B., Weld, H.A., and Schuman, E.M. (2003). Ubiquitin-
mediated proteasome activity is required for agonist-induced endocytosis of 
GluRs. Curr. Biol. 13, 2073-2081. 
56. Bingol, B., and Schuman, E.M. (2004). A proteasome-sensitive connection 
between PSD-95 and GluR1 endocytosis. Neuropharmacology 47, 755-763. 
57. Colledge, M., Snyder, E.M., Crozier, R.A., Soderling, J.A., Jin, Y.T., Langeberg, 
L.K., Lu, H., Bear, M.F., and Scott, J.D. (2003). Ubiquitination regulates PSD-95 
degradation and AMPA receptor surface expression. Neuron 40, 595-607. 
58. Racz, B., Blanpied, T.A., Ehlers, M.D., and Weinberg, R.J. (2004). Lateral 
organization of endocytic machinery in dendritic spines. Nat. Neurosci. 7, 917-
918. 
59. Ehlers, M.D. (2000). Reinsertion or degradation of AMPA receptors determined 
by activity-dependent endocytic sorting. Neuron 28, 511-525. 
60. Lee, S.H., Simonetta, A., and Sheng, M. (2004). Subunit rules governing the 
sorting of internalized AMPA receptors in hippocampal neurons. Neuron 43, 221-
236. 
61. Shepherd, J.D., and Huganir, R.L. (2007). The cell biology of synaptic plasticity: 
AMPA receptor trafficking. Annu. Rev. Cell Dev. Biol. 23, 613-643. 
62. Parton, R.G., Simons, K., and Dotti, C.G. (1992). Axonal and dendritic endocytic 
pathways in cultured neurons. J. Cell. Biol. 119, 123-137. 
63. Chiti, F., and Dobson, C.M. (2006). Protein misfolding, functional amyloid, and 
human disease. Annu. Rev. Biochem. 75, 333-366. 
64. Ding, Q., Cecarini, V., and Keller, J.N. (2007). Interplay between protein 
synthesis and degradation in the CNS: physiological and pathological 
implications. Trends Neurosci. 30, 31-36. 
65. Ross, C.A., and Poirier, M.A. (2004). Protein aggregation and neurodegenerative 
disease. Nat. Med. 10, S10-S17. 
85 
 
 
 
66. Lowe, J., Mayer, R.J., and Landon, M. (1993). Ubiquitin in neurodegenerative 
diseases. Brain Pathol. 3, 55-65. 
67. Chung, K.K., Dawson, V.L., and Dawson, T.M. (2001). The role of the ubiquitin-
proteasomal pathway in Parkinson's disease and other neurodegenerative 
disorders. Trends Neurosci. 24, S7-14. 
68. Bugiani, O. (2007). The many ways to frontotemporal degeneration and beyond. 
Neurol. Sci. 28, 241-244. 
69. Cummings, J.L. (2004). Dementia with Lewy bodies: Molecular pathogenesis and 
implications for classification. J. Geriatr. Psych. Neur. 17, 112-119. 
70. Mayer, R.J., Tipler, C., Arnold, J., Laszlo, L., Al-Khedhairy, A., Lowe, J., and 
Landon, M. (1996). Endosome-lysosomes, ubiquitin and neurodegeneration. Adv. 
Exp. Med. Biol. 389, 261-269. 
71. Anderson, J.P., Walker, D.E., Goldstein, J.M., de Laat, R., Banducci, K., 
Caccavello, R.J., Barbour, R., Huang, J., Kling, K., Lee, M., et al. (2006). 
Phosphorylation of Ser-129 is the dominant pathological modification of alpha-
synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739-
29752. 
72. Thrower, J.S., Hoffman, L., Rechsteiner, M., and Pickart, C.M. (2000). 
Recognition of the polyubiquitin proteolytic signal. EMBO J. 19, 94-102. 
73. Dahlmann, B. (2007). Role of proteasomes in disease. BMC Biochem 8 Suppl 1, 
S3. 
74. Rubinsztein, D.C. (2006). The roles of intracellular protein-degradation pathways 
in neurodegeneration. Nature 443, 780-786. 
75. Bence, N.F., Sampat, R.M., and Kopito, R.R. (2001). Impairment of the ubiquitin-
proteasome system by protein aggregation. Science 292, 1552-1555. 
76. Wang, J., Wang, C.E., Orr, A., Tydlacka, S., Li, S.H., and Li, X.J. (2008). 
Impaired ubiquitin-proteasome system activity in the synapses of Huntington's 
disease mice. J. Cell Biol. 180, 1177-1189. 
77. Lansbury, P.T., and Lashuel, H.A. (2006). A century-old debate on protein 
aggregation and neurodegeneration enters the clinic. Nature 443, 774-779. 
78. Kakizuka, A. (2008). Roles of VCP in human neurodegenerative disorders. 
Biochem. Soc. Trans. 36, 105-108. 
86 
 
 
 
79. McNaught, K.S.P., Olanow, C.W., Halliwell, B., Isacson, O., and Jenner, P. 
(2001). Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. 
Rev. Neurosci. 2, 589-594. 
80. Levine, B., and Kroemer, G. (2008). Autophagy in the pathogenesis of disease. 
Cell 132, 27-42. 
81. Shacka, J.J., Roth, K.A., and Zhang, J. (2008). The autophagy-lysosomal 
degradation pathway: role in neurodegenerative disease and therapy. Front. Biosci. 
13, 718-736. 
82. Zenker, M., Mayerle, J., Lerch, M.M., Tagariello, A., Zerres, K., Durie, P.R., 
Beier, M., Hulskamp, G., Guzman, C., Rehder, H., et al. (2005). Deficiency of 
UBR1, a ubiquitin ligase of the N-end rule pathway, causes pancreatic 
dysfunction, malformations and mental retardation (Johanson-Blizzard syndrome). 
Nat. Genet. 37, 1345-1350. 
83. Ganesh, S., Puri, R., Singh, S., Mittal, S., and Dubey, D. (2006). Recent advances 
in the molecular basis of Lafora's progressive myoclonus epilepsy. J. Hum. Genet. 
51, 1-8. 
84. Tarpey, P.S., Raymond, F.L., O'Meara, S., Edkins, S., Teague, J., Butler, A., 
Dicks, E., Stevens, C., Tofts, C., Avis, T., et al. (2007). Mutations in CUL4B, 
which encodes a ubiquitin E3 ligase subunit, cause an X-linked mental retardation 
syndrome associated with aggressive outbursts, seizures, relative macrocephaly, 
central obesity, hypogonadism, pes cavus, and tremor. Am. J. Hum. Genet. 80, 
345-352. 
85. Froyen, G., Corbett, M., Vandewalle, J., Jarvela, I., Lawrence, O., Meldrum, C., 
Bauters, M., Govaerts, K., Vandeleur, L., Van Esch, H., et al. (2008). 
Submicroscopic duplications of the hydroxysteroid dehydrogenase HSD17B10 
and the E3 ubiquitin ligase HUWE1 are associated with mental retardation. Am. J. 
Hum. Genet. 82, 432-443. 
86. Walkley, S.U. (2007). Lysosomal Disorders of the Nervous System. In 
Neurobiology of Disease, S. Gilman, ed. (Burlington, MA: Elsevier), pp. 1-18. 
87. Dauer, W., and Przedborski, S. (2003). Parkinson's disease: mechanisms and 
models. Neuron 39, 889-909. 
88. Belin, A.C., and Westerlund, M. (2008). Parkinson's disease: A genetic 
perspective. FEBS J. 275, 1377-1383. 
89. von Coelln, R., Dawson, V.L., and Dawson, T.M. (2004). Parkin-associated 
Parkinson's disease. Cell Tissue Res. 318, 175-184. 
87 
 
 
 
90. Xiong, H., Wang, D., Chen, L., Choo, Y.S., Ma, H., Tang, C., Xia, K., Jiang, W., 
Ronai, Z., Zhuang, X., et al. (2009). Parkin, PINK1, and DJ-1 form a ubiquitin E3 
ligase complex promoting unfolded protein degradation. J. Clin. Invest. 119, 650-
660. 
91. Pankratz, N., and Foroud, T. (2007). Genetics of Parkinson disease. Genet. Med. 
9, 801-811. 
92. Ichihara, N., Wu, J., Chui, D.H., Yamazaki, K., Wakabayashi, T., and Kikuchi, T. 
(1995). Axonal degeneration promotes abnormal accumulation of amyloid β-
protein in ascending gracile tract of Gracile Axonal Dystrophy (GAD) mouse. 
Brain Res. 695, 173-178. 
93. Saigoh, K., Wang, Y.L., Suh, T.G., Yamanishi, T., Sakai, Y., Kiyosawa, H., 
Harada, T., Ichihara, N., Wakana, S., Kikuchi, T., et al. (1999). Intragenic 
deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. 
Nat. Genet. 23, 47-51. 
94. Case, A., and Stein, R.L. (2006). Mechanistic studies of ubiquitin C-terminal 
hydrolase L1. Biochemistry 45, 2443-2452. 
95. Bedford, L., Hay, D., Devoy, A., Paine, S., Powe, D.G., Seth, R., Gray, T., 
Topham, I., Fone, K., Rezvani, N., et al. (2008). Depletion of 26S proteasomes in 
mouse brain neurons causes neurodegeneration and Lewy-like inclusions 
resembling human pale bodies. J. Neurosci. 28, 8189-8198. 
96. Li, Z., Arnaud, L., Rockwell, P., and Figueiredo-Pereira, M.E. (2004). A single 
amino acid substitution in a proteasome subunit triggers aggregation of 
ubiquitinated proteins in stressed neuronal cells. J. Neurochem. 90, 19-28. 
97. Bedford, L., Hay, D., Paine, S., Rezvani, N., Mee, M., Lowe, J., and Mayer, R.J. 
(2008). Is malfunction of the ubiquitin proteasome system the primary cause of 
alpha-synucleinopathies and other chronic human neurodegenerative disease? 
Biochim. Biophys. Acta 1782, 683-690. 
98. Glickman, M.H., and Raveh, D. (2005). Proteasome plasticity. FEBS Lett. 579, 
3214-3223. 
99. Schmidt, M., Hanna, J., Elsasser, S., and Finley, D. (2005). Proteasome-
associated proteins: regulation of a proteolytic machine. Biol. Chem. 386, 725-
737. 
100. Tonoki, A., Kuranaga, E., Tomioka, T., Hamazaki, J., Murata, S., Tanaka, K., and 
Miura, M. (2009). Genetic evidence linking age-dependent attenuation of the 26S 
proteasome with the aging process. Mol. Cell. Biol. 29, 1095-1106. 
88 
 
 
 
101. Noda, C., Tanahashi, N., Shimbara, N., Hendil, K.B., and Tanaka, K. (2000). 
Tissue distribution of constitutive proteasomes, immunoproteasomes, and PA28 
in rats. Biochem. Biophys. Res. Commun. 277, 348-354. 
102. Guo, L., and Wang, Y. (2007). Glutamate stimulates glutamate receptor 
interacting protein 1 degradation by ubiquitin-proteasome system to regulate 
surface expression of GluR2. Neuroscience 145, 100-109. 
103. Djakovic, S.N., Schwarz, L.A., Barylko, B., Demartino, G.N., and Patrick, G.N. 
(2009). Regulation of the proteasome by neuronal activity and CAMKII. J. Biol. 
Chem. 
104. Besche, H., Haas, W., Gygi, S., and Goldberg, A. (2009). Isolation of mammalian 
26S proteasomes and p97/VCP complexes using the ubiquitin-like domain from 
HHR23B reveals novel proteasome-associated proteins. Biochemistry 48, 2538–
2549. 
105. Scanlon, T.C., Gottlieb, B., Durcan, T.M., Fon, E.A., Beitel, L.K., and Trifiro, 
M.A. (2009). Isolation of human proteasomes and putative proteasome-interacting 
proteins using a novel affinity chromatography method. Exp. Cell Res. 315, 176-
189. 
106. Wang, X.R., and Huang, L. (2008). Identifying dynamic interactors of protein 
complexes by quantitative mass spectrometry. Mol. Cell. Proteomics 7, 46-57. 
107. Schauber, C., Chen, L., Tongaonkar, P., Vega, I., Lambertson, D., Potts, W., and 
Madura, K. (1998). Rad23 links DNA repair to the ubiquitin/proteasome pathway. 
Nature 391, 715-718. 
108. Funakoshi, M., Tomko, R.J., Jr., Kobayashi, H., and Hochstrasser, M. (2009). 
Multiple assembly chaperones govern biogenesis of the proteasome regulatory 
particle base. Cell 137, 887-899. 
109. Kaneko, T., Hamazaki, J., Iemura, S., Sasaki, K., Furuyama, K., Natsume, T., 
Tanaka, K., and Murata, S. (2009). Assembly pathway of the Mammalian 
proteasome base subcomplex is mediated by multiple specific chaperones. Cell 
137, 914-925. 
110. Le Tallec, B., Barrault, M.B., Guerois, R., Carre, T., and Peyroche, A. (2009). 
Hsm3/S5b participates in the assembly pathway of the 19S regulatory particle of 
the proteasome. Mol. Cell 33, 389-399. 
111. Park, S., Roelofs, J., Kim, W., Robert, J., Schmidt, M., Gygi, S.P., and Finley, D. 
(2009). Hexameric assembly of the proteasomal ATPases is templated through 
their C termini. Nature 459, 866-870. 
89 
 
 
 
112. Roelofs, J., Park, S., Haas, W., Tian, G., McAllister, F.E., Huo, Y., Lee, B.-H., 
Zhang, F., Shi, Y., Gygi, S.P., et al. (2009). Chaperone-mediated pathway of 
proteasome regulatory particle assembly. Nature 459, 861-865. 
113. Saeki, Y., Toh, E.A., Kudo, T., Kawamura, H., and Tanaka, K. (2009). Multiple 
Proteasome-Interacting Proteins Assist the Assembly of the Yeast 19S Regulatory 
Particle. Cell 137, 900-913. 
114. Hanna, J., and Finley, D. (2007). A proteasome for all occasions. FEBS Lett. 581, 
2854-2861. 
115. Sakata, E., Yamaguchi, Y., Kurimoto, E., Kikuchi, J., Yokoyama, S., Yamada, S., 
Kawahara, H., Yokosawa, H., Hattori, N., Mizuno, Y., et al. (2003). Parkin binds 
the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO 
Rep. 4, 301-306. 
116. McCutchen-Maloney, S.L., Matsuda, K., Shimbara, N., Binns, D.D., Tanaka, K., 
Slaughter, C.A., and DeMartino, G.N. (2000). cDNA cloning, expression, and 
functional characterization of PI31, a proline-rich inhibitor of the proteasome. J 
Biol Chem 275, 18557-18565. 
117. Dreveny, I., Pye, V.E., Beuron, F., Briggs, L.C., Isaacson, R.L., Matthews, S.J., 
McKeown, C., Yuan, X., Zhang, X., and Freemont, P.S. (2004). p97 and close 
encounters of every kind: a brief review. Biochem. Soc. Trans. 32, 715-720. 
118. Iha, H., Peloponese, J.M., Verstrepen, L., Zapart, G., Ikeda, F., Smith, C.D., 
Starost, M.F., Yedavalli, V., Heyninck, K., Dikic, I., et al. (2008). Inflammatory 
cardiac valvulitis in TAX1BP1-deficient mice through selective NF-kappaB 
activation. EMBO J. 27, 629-641. 
119. Seibenhener, M.L., Babu, J.R., Geetha, T., Wong, H.C., Krishna, N.R., and 
Wooten, M.W. (2004). Sequestosome 1/p62 is a polyubiquitin chain binding 
protein involved in ubiquitin proteasome degradation. Mol. Cell. Biol. 24, 8055-
8068. 
120. Tasaki, T., and Kwon, Y.T. (2007). The mammalian N-end rule pathway: new 
insights into its components and physiological roles. Trends Biochem. Sci. 32, 
520-528. 
121. Arndt, V., Rogon, C., and Hohfeld, J. (2007). To be, or not to be—molecular 
chaperones in protein degradation. Cell. Mol. Life Sci. 64, 2525-2541. 
122. Song, E.J., Yim, S.H., Kim, E., Kim, N.S., and Lee, K.J. (2005). Human Fas-
associated factor 1, interacting with ubiquitinated proteins and valosin-containing 
protein, is involved in the ubiquitin-proteasome pathway. Mol. Cell. Biol. 25, 
2511-2524. 
90 
 
 
 
123. Wiseman, R.L., Chin, K.-T., Haynes, C.M., Stanhill, A., Xu, C.-F., Roguev, A., 
Krogan, N.J., Neubert, T.A., and Ron, D. (2009). Thioredoxin related protein 32 
is an arsenite-regulated thiol reductase of the proteasome 19S particle. J. Biol. 
Chem. 284, 15233-15245. 
124. Andersen, K.M., Madsen, L., Prag, S., Johnsen, A.H., Semple, C.A., Hendi, K.B., 
and Hartmann Petersen, R. (2009). Thioredoxin Txnl1/TRP32 is a redox active 
co-factor of the 26S proteasome. J. Biol. Chem. 284, 15246-15254. 
125. Hartmann-Petersen, R., and Gordon, C. (2004). Integral UBL domain proteins: a 
family of proteasome interacting proteins. Semin. Cell. Dev. Biol. 15, 247-259. 
126. Leggett, D.S., Hanna, J., Borodovsky, A., Crosas, B., Schmidt, M., Baker, R.T., 
Walz, T., Ploegh, H., and Finley, D. (2002). Multiple associated proteins regulate 
proteasome structure and function. Mol. Cell 10, 495-507. 
127. Kleijnen, M.F., Roelofs, J., Park, S., Hathaway, N.A., Glickman, M., King, R.W., 
and Finley, D. (2007). Stability of the proteasome can be regulated allosterically 
through engagement of its proteolytic active sites. Nat. Struct. Mol. Biol. 14, 
1180-1188. 
128. Watanabe, T.K., Saito, A., Suzuki, M., Fujiwara, T., Takahashi, E., Slaughter, 
C.A., DeMartino, G.N., Hendil, K.B., Chung, C.H., Tanahashi, N., et al. (1998). 
cDNA cloning and characterization of a human proteasomal modulator subunit, 
p27 (PSMD9). Genomics 50, 241-250. 
129. Donato, R. (2003). Intracellular and extracellular roles of S100 proteins. Microsc. 
Res. Tech. 60, 540-551. 
130. Bridges, D., and Moorhead, G.B. (2004). 14-3-3 proteins: a number of functions 
for a numbered protein. Sci. STKE 2004, re10. 
131. Kriegenburg, F., Seeger, M., Saeki, Y., Tanaka, K., Lauridsen, A.M., Hartmann-
Petersen, R., and Hendil, K.B. (2008). Mammalian 26S proteasomes remain intact 
during protein degradation. Cell 135, 355-365. 
132. Malenka, R.C., and Bear, M.F. (2004). LTP and LTD: an embarrassment of riches. 
Neuron 44, 5-21. 
133. Shembade, N., Harhaj, N.S., Parvatiyar, K., Copeland, N.G., Jenkins, N.A., 
Matesic, L.E., and Harhaj, E.W. (2008). The E3 ligase Itch negatively regulates 
inflammatory signaling pathways by controlling the function of the ubiquitin-
editing enzyme A20. Nat. Immunol. 9, 254-262. 
134. Takahashi, H., Yamazaki, H., Hanamura, K., Sekino, Y., and Shirao, T. (2009). 
Activity of the AMPA receptor regulates drebrin stabilization in dendritic spine 
morphogenesis. J. Cell Sci. 122, 1211-1219. 
91 
 
 
 
135. DeBello, W.M., O'Connor, V., Dresbach, T., Whiteheart, S.W., Wang, S.S., 
Schweizer, F.E., Betz, H., Rothman, J.E., and Augustine, G.J. (1995). SNAP-
mediated protein-protein interactions essential for neurotransmitter release. 
Nature 373, 626-630. 
136. Montecucco, C., Schiavo, G., and Pantano, S. (2005). SNARE complexes and 
neuroexocytosis: how many, how close? Trends Biochem. Sci. 30, 367-372. 
137. Wilson, S.M., Bhattacharyya, B., Rachel, R.A., Coppola, V., Tessarollo, L., 
Householder, D.B., Fletcher, C.F., Miller, R.J., Copeland, N.G., and Jenkins, N.A. 
(2002). Synaptic defects in ataxia mice result from a mutation in Usp14, encoding 
a ubiquitin-specific protease. Nat. Genet. 32, 420-425. 
138. Crimmins, S., Jin, Y., Wheeler, C., Huffman, A.K., Chapman, C., Dobrunz, L.E., 
Levey, A., Roth, K.A., Wilson, J.A., and Wilson, S.M. (2006). Transgenic rescue 
of ataxia mice with neuronal-specific expression of ubiquitin-specific protease 14. 
J. Neurosci. 26, 11423-11431. 
139. Koulich, E., Li, X., and DeMartino, G.N. (2008). Relative structural and 
functional roles of multiple deubiquitylating proteins associated with mammalian 
26S proteasome. Mol. Biol. Cell 19, 1072-1082. 
140. Jiang, J., Parameshwaran, K., Seibenhener, M.L., Kang, M.G., Suppiramaniam, 
V., Huganir, R.L., Diaz-Meco, M.T., and Wooten, M.W. (2009). AMPA receptor 
trafficking and synaptic plasticity require SQSTM1/p62. Hippocampus 19, 392-
406. 
141. Ulrich, M., Seeber, S., Becker, C.M., and Enz, R. (2007). Tax1-binding protein 1 
is expressed in the retina and interacts with the GABA(C) receptor rho1 subunit. 
Biochem. J. 401, 429-436. 
142. Aakalu, G., Smith, W.B., Nguyen, N., Jiang, C., and Schuman, E.M. (2001). 
Dynamic visualization of local protein synthesis in hippocampal neurons. Neuron 
30, 489-502. 
143. Gordon-Weeks, P.R. (1987). Isolation of synaptosomes, growth cones and their 
subcellular components. In Neurochemistry: A Practical Approach, A.J. Turner 
and H.S. Bachelard, eds. (Oxford: IRL), pp. 1-26. 
144. Dohmen, R.J., London, M.K., Glanemann, C., and Ramos, P.C. (2005). Assays 
for proteasome assembly and maturation. In Methods in Molecular Biology, Vol. 
301, Ubiquitin-Proteasome Protocols, C. Patterson and D.M. Cyr, eds. (Totowa, 
NJ: Humana), pp. 243-254. 
145. Haas, W., Faherty, B.K., Gerber, S.A., Elias, J.E., Beausoleil, S.A., Bakalarski, 
C.E., Li, X., Villen, J., and Gygi, S.P. (2006). Optimization and use of peptide 
92 
 
 
 
mass measurement accuracy in shotgun proteomics. Mol. Cell. Proteomics 5, 
1326-1337. 
146. Elias, J.E., and Gygi, S.P. (2007). Target-decoy search strategy for increased 
confidence in large-scale protein identifications by mass spectrometry. Nat. 
Methods 4, 207-214. 
147. Hou, L., Antion, M.D., Hu, D., Spencer, C.M., Paylor, R., and Klann, E. (2006). 
Dynamic translational and proteasomal regulation of fragile X mental retardation 
protein controls mGluR-dependent long-term depression. Neuron 51, 441-454. 
148. Lee, H.K., Kameyama, K., Huganir, R.L., and Bear, M.F. (1998). NMDA induces 
long-term synaptic depression and dephosphorylation of the GluR1 subunit of 
AMPA receptors in hippocampus. Neuron 21, 1151-1162. 
149. Poppek, D., and Grune, T. (2006). Proteasomal defense of oxidative protein 
modifications. Antioxid. Redox. Signal. 8, 173-184. 
150. Shringarpure, R., Grune, T., and Davies, K.J.A. (2001). Protein oxidation and 20S 
proteasome-dependent proteolysis in mammalian cells. Cell. Mol. Life Sci. 58, 
1442-1450. 
151. Davidson, H.T., Xiao, J., Dai, R., and Bergson, C. (2009). Calcyon is necessary 
for activity-dependent AMPA receptor internalization and LTD in CA1 neurons 
of hippocampus. Eur. J. Neurosci. 29, 42-54. 
152. Bajorek, M., Finley, D., and Glickman, M.H. (2003). Proteasome disassembly and 
downregulation is correlated with viability during stationary phase. Curr. Biol. 13, 
1140-1144. 
153. Lalande, M., and Calciano, M.A. (2007). Molecular epigenetics of Angelman 
syndrome. Cell. Mol. Life Sci. 64, 947-960. 
154. Jiang, Y.H., Armstrong, D., Albrecht, U., Atkins, C.M., Noebels, J.L., Eichele, G., 
Sweatt, J.D., and Beaudet, A.L. (1998). Mutation of the Angelman ubiquitin 
ligase in mice causes increased cytoplasmic p53 and deficits of contextual 
learning and long-term potentiation. Neuron 21, 799-811. 
155. Dindot, S.V., Antalffy, B.A., Bhattacharjee, M.B., and Beaudet, A.L. (2008). The 
Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and 
maternal deficiency results in abnormal dendritic spine morphology. Hum. Mol. 
Genet. 17, 111-118. 
156. Aguilaniu, H., Gustafsson, L., Rigoulet, M., and Nystrom, T. (2003). Asymmetric 
inheritance of oxidatively damaged proteins during cytokinesis. Science 299, 
1751-1753. 
93 
 
 
 
157. Mitch, W.E., and Goldberg, A.L. (1996). Mechanisms of muscle wasting. The 
role of the ubiquitin-proteasome pathway. N. Engl. J. Med. 335, 1897-1905. 
158. Watts, G.D., Wymer, J., Kovach, M.J., Mehta, S.G., Mumm, S., Darvish, D., 
Pestronk, A., Whyte, M.P., and Kimonis, V.E. (2004). Inclusion body myopathy 
associated with Paget disease of bone and frontotemporal dementia is caused by 
mutant valosin-containing protein. Nat. Genet. 36, 377-381. 
159. Neumann, M., Mackenzie, I.R., Cairns, N.J., Boyer, P.J., Markesbery, W.R., 
Smith, C.D., Taylor, J.P., Kretzschmar, H.A., Kimonis, V.E., and Forman, M.S. 
(2007). TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP 
gene mutations. J. Neuropathol. Exp. Neurol. 66, 152-157. 
160. Gitcho, M.A., Strider, J., Carter, D., Taylor-Reinwald, L., Forman, M.S., Goate, 
A.M., and Cairns, N.J. (2009). VCP mutations causing frontotemporal lobar 
degeneration disrupt localization of TDP-43 and induce cell death. J. Biol. Chem. 
284, 12384-12398. 
161. Neumann, M. (2009). Molecular Neuropathology of TDP-43 Proteinopathies. Int. 
J. Mol. Sci. 10, 232-246. 
162. Ramesh Babu, J., Lamar Seibenhener, M., Peng, J., Strom, A.L., Kemppainen, R., 
Cox, N., Zhu, H., Wooten, M.C., Diaz-Meco, M.T., Moscat, J., et al. (2008). 
Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and 
neurodegeneration. J. Neurochem. 106, 107-120. 
163. Nakashima-Yasuda, H., Uryu, K., Robinson, J., Xie, S.X., Hurtig, H., Duda, J.E., 
Arnold, S.E., Siderowf, A., Grossman, M., Leverenz, J.B., et al. (2007). Co-
morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta 
Neuropathol. 114, 221-229. 
164. Bedford, L., Paine, S., Rezvani, N., Mee, M., Lowe, J., and Mayer, R.J. (2009). 
The UPS and autophagy in chronic neurodegenerative disease: six of one and half 
a dozen of the other—or not? Autophagy 5, 224-227. 
165. Finley, D. (2009). Recognition and processing of ubiquitin-protein conjugates by 
the proteasome. Annu. Rev. Biochem. 78, 477-513. 
166. Dahlmann, B. (2007). Role of proteasomes in disease. BMC Biochem. 8 Supple. 1, 
S3-S14. 
167. Li, S., Hong, S., Shepardson, N.E., Walsh, D.M., Shankar, G.M., and Selkoe, D. 
(2009). Soluble oligomers of amyloid Beta protein facilitate hippocampal long-
term depression by disrupting neuronal glutamate uptake. Neuron 62, 788-801. 
 
 
94 
 
 
 
Vita . 
 
 
      
     Hwan-Ching Tai was born on June 18, 1978, in Taipei, Taiwan, the eldest child of Dr. 
Yi-Der Tai and Kuen-Jing Lien. His name in Chinese is 戴桓青 (pinyin Romanization: 
dai huan qing). He grew up in Taiwan and graduated from Taipei Municipal Jianguo 
High School in 1996, and later received a Bachelor of Science degree in chemistry at 
National Taiwan University in 2000. He also lived in Atlanta, Georgia for a year when he 
was ten, and since then has been known as Bruce to many friends. Although he cannot 
recall how that name was chosen, it had nothing to do with Bruce Lee. During 2000–
2002, he completed his mandatory service in the Taiwanese military. In 2002 he entered 
the chemistry Ph.D. program at the California Institute of Technology.    
